Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
less,32726002,Relative attenuation ratios,"Relative attenuation ratios were less than 1, indicating a slower central versus peripheral attenuation, across the time points for all antipsychotic types and doses with only a few exceptions.",Dissociation in Pharmacokinetic Attenuation Between Central Dopamine D2 Receptor Occupancy and Peripheral Blood Concentration of Antipsychotics: A Systematic Review. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32726002/),,1,3875,DB00363,Clozapine
,11291746,elimination half-life,"After an intraperitoneal dose of 10 mg kg(-1), the compound attained mean maximum plasma concentrations within 5 min of dosing, then declined with a mean elimination half-life of approximately 1 h.","Distribution of the methylpiperazinopyridobenzoxazepine derivative JL13, a potential antipsychotic, in rat brain. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11291746/),h,1,4133,DB00363,Clozapine
,9108654,plasma,"Although the mean daily dosage at week 12 (373 +/- 90 mg/day) was lower than that reported in American trials (444 mg/day), the mean plasma clozapine concentration attained (1,078 +/- 385 ng/ml) was higher.",Clinical evaluation and plasma clozapine concentrations in Chinese patients with schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9108654/),[ng] / [ml],"1,078",14345,DB00363,Clozapine
,10445377,AUC,"In schizophrenic patients, FLV resulted in a pronounced increased in CLZ plasma concentrations with the total mean CLZ AUC increased by a factor of 2.58 from 780.8 ng/ml per hour to 2218.0 ng/ml per hour (P<0.001).",In-vitro and in-vivo evaluation of the drug-drug interaction between fluvoxamine and clozapine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445377/),[ng] / [h·ml],780.8,15626,DB00363,Clozapine
,10445377,AUC,"In schizophrenic patients, FLV resulted in a pronounced increased in CLZ plasma concentrations with the total mean CLZ AUC increased by a factor of 2.58 from 780.8 ng/ml per hour to 2218.0 ng/ml per hour (P<0.001).",In-vitro and in-vivo evaluation of the drug-drug interaction between fluvoxamine and clozapine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10445377/),[ng] / [h·ml],2218.0,15627,DB00363,Clozapine
,19349931,Apparent volume of distribution,Apparent volume of distribution was fixed to a previously reported value in the literature of 7 L/kg.,Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19349931/),[l] / [kg],7,19936,DB00363,Clozapine
,19349931,oral clearance,"The population-predicted oral clearance of clozapine and norclozapine was 18.0 and 39.0 L/h, respectively; both the predicted clearance values vary nearly 6-fold (range, 9.18-59.06 and 16.29-97.84 L/h, respectively).",Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19349931/),[l] / [h],18.0,19937,DB00363,Clozapine
,19349931,oral clearance,"The population-predicted oral clearance of clozapine and norclozapine was 18.0 and 39.0 L/h, respectively; both the predicted clearance values vary nearly 6-fold (range, 9.18-59.06 and 16.29-97.84 L/h, respectively).",Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19349931/),[l] / [h],39.0,19938,DB00363,Clozapine
,19349931,clearance,"The population-predicted oral clearance of clozapine and norclozapine was 18.0 and 39.0 L/h, respectively; both the predicted clearance values vary nearly 6-fold (range, 9.18-59.06 and 16.29-97.84 L/h, respectively).",Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19349931/),[l] / [h],9.18-59.06,19939,DB00363,Clozapine
,19349931,clearance,"The population-predicted oral clearance of clozapine and norclozapine was 18.0 and 39.0 L/h, respectively; both the predicted clearance values vary nearly 6-fold (range, 9.18-59.06 and 16.29-97.84 L/h, respectively).",Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19349931/),[l] / [h],16.29-97.84,19940,DB00363,Clozapine
,19349931,oral clearance,"For clozapine, smokers and males showed increased oral clearance by 6.0 and 4.5 L/h, respectively.",Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19349931/),[l] / [h],6.0,19941,DB00363,Clozapine
,19349931,oral clearance,"For clozapine, smokers and males showed increased oral clearance by 6.0 and 4.5 L/h, respectively.",Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19349931/),[l] / [h],4.5,19942,DB00363,Clozapine
,19349931,oral clearance,"For norclozapine, smokers and male gender were associated with an increased oral clearance of 11.3 and 7.6 L/h, respectively.",Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19349931/),[l] / [h],11.3,19943,DB00363,Clozapine
,19349931,oral clearance,"For norclozapine, smokers and male gender were associated with an increased oral clearance of 11.3 and 7.6 L/h, respectively.",Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19349931/),[l] / [h],7.6,19944,DB00363,Clozapine
,19349931,Ka,The formulation of clozapine administered had an impact on the absorption rate with a Ka of 0.14/h for tablet and 10.3/h for the suspension form.,Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19349931/),1/[h],0.14,19945,DB00363,Clozapine
,19349931,Ka,The formulation of clozapine administered had an impact on the absorption rate with a Ka of 0.14/h for tablet and 10.3/h for the suspension form.,Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19349931/),1/[h],10.3,19946,DB00363,Clozapine
,28324647,efflux ratio,"In vitro assessment demonstrated that CNO is a substrate for P-glycoprotein (Pgp; efflux ratio, 20), thus providing a likely mechanism limiting CNO levels in the CNS.",Metabolism and Distribution of Clozapine-N-oxide: Implications for Nonhuman Primate Chemogenetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28324647/),,20,22879,DB00363,Clozapine
,12220025,peak concentration,"The calculated peak concentration of clozapine in this dog was approximately 6,000 ng/mL, and the elimination half-life (t(1/2)) was 5 hours.",Clozapine intoxication in a dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12220025/),[ng] / [ml],"6,000",25314,DB00363,Clozapine
,12220025,elimination half-life (t(1/2)),"The calculated peak concentration of clozapine in this dog was approximately 6,000 ng/mL, and the elimination half-life (t(1/2)) was 5 hours.",Clozapine intoxication in a dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12220025/),h,5,25315,DB00363,Clozapine
,8216694,half-life,"Levels peaked within 30 minutes, and elimination of CLZ from brain and CLZ or NOR from blood was very rapid (half-life = 1.5 to 1.6 hours).",Tissue concentrations of clozapine and its metabolites in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8216694/),h,1.5 to 1.6,27568,DB00363,Clozapine
,15289794,initial,"On cessation of smoking, initial caffeine clearance (estimated geometric means and 95% confidence intervals) decreased significantly (P <.01), by 36.1% (30.9%-42.2%), from 2.47 mL. min(-1).",Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289794/),[ml] / [min],2.47,33852,DB00363,Clozapine
,15289794,clearance,"On cessation of smoking, initial caffeine clearance (estimated geometric means and 95% confidence intervals) decreased significantly (P <.01), by 36.1% (30.9%-42.2%), from 2.47 mL. min(-1).",Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289794/),[ml] / [min],2.47,33853,DB00363,Clozapine
,15289794,new steady state,kg(-1) body weight) to a new steady state of 1.53 mL. min(-1).,Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289794/),[ml] / [min],1.53,33854,DB00363,Clozapine
,15289794,apparent half-life,The apparent half-life of CYP1A2 activity decrease was 38.6 hours (27.4-54.4 hours).,Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289794/),h,38.6,33855,DB00363,Clozapine
,23625418,minimum injection volume,The validated method offers the advantage of using minimum injection volume (25μl) and plasma sample volume (300μl).,Development and validation of high performance liquid chromatographic method for analysis of clozapine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23625418/),,25,35590,DB00363,Clozapine
,1683340,tmax,"There was a dose-dependent increase in zotepine plasma levels with a tmax between 2-4 hours post-drug and cmax: 6.9, 14.8 and 19.6 ng/ml for the 3 doses, respectively and a slow decline thereafter.",[Relation between blood levels and average quantitative EEG and psychometrically assessed pharmacodynamic changes following zotepine]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1683340/),h,2-4,49273,DB00363,Clozapine
,1683340,cmax,"There was a dose-dependent increase in zotepine plasma levels with a tmax between 2-4 hours post-drug and cmax: 6.9, 14.8 and 19.6 ng/ml for the 3 doses, respectively and a slow decline thereafter.",[Relation between blood levels and average quantitative EEG and psychometrically assessed pharmacodynamic changes following zotepine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1683340/),[ng] / [ml],6.9,49274,DB00363,Clozapine
,1683340,cmax,"There was a dose-dependent increase in zotepine plasma levels with a tmax between 2-4 hours post-drug and cmax: 6.9, 14.8 and 19.6 ng/ml for the 3 doses, respectively and a slow decline thereafter.",[Relation between blood levels and average quantitative EEG and psychometrically assessed pharmacodynamic changes following zotepine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1683340/),[ng] / [ml],14.8,49275,DB00363,Clozapine
,1683340,cmax,"There was a dose-dependent increase in zotepine plasma levels with a tmax between 2-4 hours post-drug and cmax: 6.9, 14.8 and 19.6 ng/ml for the 3 doses, respectively and a slow decline thereafter.",[Relation between blood levels and average quantitative EEG and psychometrically assessed pharmacodynamic changes following zotepine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1683340/),[ng] / [ml],19.6,49276,DB00363,Clozapine
,9723115,total clearances,"2. Using a general pharmacokinetic model for the interconversion process, the mean total clearances of clozapine and CNO were 28.45 L/hr and 45.30 L/hr, respectively.",Reversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9723115/),[l] / [h],28.45,49600,DB00363,Clozapine
,9723115,total clearances,"2. Using a general pharmacokinetic model for the interconversion process, the mean total clearances of clozapine and CNO were 28.45 L/hr and 45.30 L/hr, respectively.",Reversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9723115/),[l] / [h],45.30,49601,DB00363,Clozapine
,9723115,plasma concentrations,"3. When administered clozapine, mean CNO plasma concentrations of 17.7 +/- 16.4 ng/ml were slightly lower than the other clozapine metabolite-desmethylclozapine (DCLOZ) plasma levels of 24.4 +/- 8.6 ng/ml at the 12 hour time point.",Reversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9723115/),[ng] / [m],17,49602,DB00363,Clozapine
,9723115,plasma,"3. When administered clozapine, mean CNO plasma concentrations of 17.7 +/- 16.4 ng/ml were slightly lower than the other clozapine metabolite-desmethylclozapine (DCLOZ) plasma levels of 24.4 +/- 8.6 ng/ml at the 12 hour time point.",Reversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9723115/),ng,24.4,49603,DB00363,Clozapine
,9723115,plasma concentrations,"When CNO was administered, plasma concentrations at the 12 hour time point of clozapine were twice the amount of CNO (28.1 +/- 8.9 ng/ml vs 14.4 +/- 8.8 ng/ml).",Reversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9723115/),[ng] / [ml],28,49604,DB00363,Clozapine
,9723115,plasma concentrations,"When CNO was administered, plasma concentrations at the 12 hour time point of clozapine were twice the amount of CNO (28.1 +/- 8.9 ng/ml vs 14.4 +/- 8.8 ng/ml).",Reversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9723115/),[ng] / [ml],14.4,49605,DB00363,Clozapine
,29427293,half-life,The half-life of FL3-fluorescence was estimated at 228 h (coefficient of variation 35%).,Development of a nomogram for the estimation of long-term adherence to clozapine therapy using neutrophil fluorescence. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29427293/),h,228,52239,DB00363,Clozapine
,21890297,flow rate,"Plasma samples (100 μl) were pretreated by protein precipitation with the mixture of 3% formic acid and 50 ng/ml clozapine (internal standard) in acetonitrile followed by LC analysis using a C(18) column and a mobile phase composed of 0.4% formic acid solution and 0.2% formic acid solution of methanol (60:40, v/v) operated at a flow rate of 0.4 ml/min.","Determination of berberine, palmatine and jatrorrhizine in rabbit plasma by liquid chromatography-electrospray ionization-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21890297/),[ml] / [min],0.4,60968,DB00363,Clozapine
more,21890297,absolute recovery,The mean absolute recovery was more than 72% for all analytes.,"Determination of berberine, palmatine and jatrorrhizine in rabbit plasma by liquid chromatography-electrospray ionization-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21890297/),%,72,60969,DB00363,Clozapine
,9384461,clearances CL/F,"Men had higher clearances CL/F (median with 25% and 75% quartiles 38.2 (22.0, 60.0) vs 28.3 (15.2, 48.6) l h(-1)) and a larger volume of distribution V/F (694 (224, 970) vs 401 (189, 932) l) than women.",Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9384461/),[l] / [h],38.2,62924,DB00363,Clozapine
,9384461,clearances CL/F,"Men had higher clearances CL/F (median with 25% and 75% quartiles 38.2 (22.0, 60.0) vs 28.3 (15.2, 48.6) l h(-1)) and a larger volume of distribution V/F (694 (224, 970) vs 401 (189, 932) l) than women.",Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9384461/),[l] / [h],28.3,62925,DB00363,Clozapine
,9384461,volume of distribution V/F,"Men had higher clearances CL/F (median with 25% and 75% quartiles 38.2 (22.0, 60.0) vs 28.3 (15.2, 48.6) l h(-1)) and a larger volume of distribution V/F (694 (224, 970) vs 401 (189, 932) l) than women.",Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9384461/),l,694,62926,DB00363,Clozapine
,9384461,volume of distribution V/F,"Men had higher clearances CL/F (median with 25% and 75% quartiles 38.2 (22.0, 60.0) vs 28.3 (15.2, 48.6) l h(-1)) and a larger volume of distribution V/F (694 (224, 970) vs 401 (189, 932) l) than women.",Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9384461/),l,401,62927,DB00363,Clozapine
,7542676,absolute oral bioavailability,"The absolute oral bioavailability of risperidone is nearly 70%, and after oral administration, it is rapidly absorbed with the plasma level reaching a peak at about 1 h.","A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7542676/),%,70,63037,DB00363,Clozapine
,17822717,serum terminal half-life,"Single-dose pharmacokinetic analysis revealed a serum terminal half-life of 1.2-1.5 h for each drug, with no sex differences.",Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17822717/),h,1.2-1.5,64590,DB00363,Clozapine
,33957192,inhibition constants,"Experiments in vitro indicated that CLZ competitively inhibited the conversion of RIS to 9-hydroxy-RIS with the inhibition constants of 1.36 and 3.0 μM in rat and human liver microsomes, respectively.",Clozapine affects the pharmacokinetics of risperidone and inhibits its metabolism and P-glycoprotein-mediated transport in vivo and in vitro: A safety attention to antipsychotic polypharmacy with clozapine and risperidone. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33957192/),μM,1.36,66266,DB00363,Clozapine
,33957192,inhibition constants,"Experiments in vitro indicated that CLZ competitively inhibited the conversion of RIS to 9-hydroxy-RIS with the inhibition constants of 1.36 and 3.0 μM in rat and human liver microsomes, respectively.",Clozapine affects the pharmacokinetics of risperidone and inhibits its metabolism and P-glycoprotein-mediated transport in vivo and in vitro: A safety attention to antipsychotic polypharmacy with clozapine and risperidone. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33957192/),μM,3.0,66267,DB00363,Clozapine
,10945320,terminal elimination half-life,Decline in serum quetiapine concentration followed a biexponential pattern with a terminal elimination half-life of 22 hours.,Quetiapine fumarate overdose: clinical and pharmacokinetic lessons from extreme conditions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10945320/),h,22,71498,DB00363,Clozapine
,10945320,terminal elimination half-life,Elevated serum concentrations associated with this overdose remained above the limit of detection long enough to document a terminal elimination half-life of 22 hours in this patient.,Quetiapine fumarate overdose: clinical and pharmacokinetic lessons from extreme conditions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10945320/),h,22,71499,DB00363,Clozapine
,10945320,half-life,This is much more consistent with previously noted duration of clinical effects and detectable serum concentrations after overdose than the published half-life of 6 hours.,Quetiapine fumarate overdose: clinical and pharmacokinetic lessons from extreme conditions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10945320/),h,6,71500,DB00363,Clozapine
,18370516,elimination rate constants from compartments 1 (,"The mean elimination rate constants from compartments 1 (k(10)) and 2 (k(20 ), elimination rate constant of norclozapine) were 0.087 and 0.156h(-1), respectively.",A Kinetic Model for Simultaneous Fit of Clozapine and Norclozapine Concentrations in Chronic Schizophrenic Patients during Long-Term Treatment. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370516/),1/[h],0.087,75605,DB00363,Clozapine
,18370516,k(10),"The mean elimination rate constants from compartments 1 (k(10)) and 2 (k(20 ), elimination rate constant of norclozapine) were 0.087 and 0.156h(-1), respectively.",A Kinetic Model for Simultaneous Fit of Clozapine and Norclozapine Concentrations in Chronic Schizophrenic Patients during Long-Term Treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370516/),1/[h],0.087,75606,DB00363,Clozapine
,18370516,k(20 ),"The mean elimination rate constants from compartments 1 (k(10)) and 2 (k(20 ), elimination rate constant of norclozapine) were 0.087 and 0.156h(-1), respectively.",A Kinetic Model for Simultaneous Fit of Clozapine and Norclozapine Concentrations in Chronic Schizophrenic Patients during Long-Term Treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370516/),1/[h],0.087,75607,DB00363,Clozapine
,18370516,elimination rate constant,"The mean elimination rate constants from compartments 1 (k(10)) and 2 (k(20 ), elimination rate constant of norclozapine) were 0.087 and 0.156h(-1), respectively.",A Kinetic Model for Simultaneous Fit of Clozapine and Norclozapine Concentrations in Chronic Schizophrenic Patients during Long-Term Treatment. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370516/),1/[h],0.156,75608,DB00363,Clozapine
,18370516,rate of formation,"The rate of formation of norclozapine, k(12), averaged 1.25h(-1).",A Kinetic Model for Simultaneous Fit of Clozapine and Norclozapine Concentrations in Chronic Schizophrenic Patients during Long-Term Treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370516/),1/[h],1.25,75609,DB00363,Clozapine
,18370516,apparent clearance of clozapine (CL/F),The apparent clearance of clozapine (CL/F) averaged 44.7 L/h and the volume of distribution (V(c)/F) was 7.00 L/kg.,A Kinetic Model for Simultaneous Fit of Clozapine and Norclozapine Concentrations in Chronic Schizophrenic Patients during Long-Term Treatment. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370516/),[l] / [h],44.7,75610,DB00363,Clozapine
,18370516,volume of distribution (V(c)/F),The apparent clearance of clozapine (CL/F) averaged 44.7 L/h and the volume of distribution (V(c)/F) was 7.00 L/kg.,A Kinetic Model for Simultaneous Fit of Clozapine and Norclozapine Concentrations in Chronic Schizophrenic Patients during Long-Term Treatment. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370516/),[l] / [kg],7.00,75611,DB00363,Clozapine
,20606310,Volume of distribution,Volume of distribution of topiramate was 0.518 l/kg.,A nonlinear mixed effects modelling analysis of topiramate pharmacokinetics in patients with epilepsy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20606310/),[l] / [kg],0.518,78908,DB00363,Clozapine
,20606310,oral clearance,"For a typical patient oral clearance was estimated at 1.47 l/h, with interindividual variability of 39.2%.",A nonlinear mixed effects modelling analysis of topiramate pharmacokinetics in patients with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20606310/),[l] / [h],1.47,78909,DB00363,Clozapine
,33737093,Cmax,"The single-dose in vivo pharmacokinetic analysis in the rat model showed a substantial increase in the therapeutic concentration of clozapine in the brain tissue in the case of intranasal nanosuspension (dose = 0.05 mg drug/0.1 mL, Cmax = 8.62 ± 0.45 μg/g, tmax = 1 h) compared to conventional oral clozapine suspension (dose = 26.43 mg drug/0.158 mL, Cmax = 1.14 ± 0.12 μg/g, tmax = 1 h).",Nose to brain delivery of tailored clozapine nanosuspension stabilized using (+)-alpha-tocopherol polyethylene glycol 1000 succinate: Optimization and in vivo pharmacokinetic studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33737093/),[μg] / [g],8.62,85286,DB00363,Clozapine
,33737093,tmax,"The single-dose in vivo pharmacokinetic analysis in the rat model showed a substantial increase in the therapeutic concentration of clozapine in the brain tissue in the case of intranasal nanosuspension (dose = 0.05 mg drug/0.1 mL, Cmax = 8.62 ± 0.45 μg/g, tmax = 1 h) compared to conventional oral clozapine suspension (dose = 26.43 mg drug/0.158 mL, Cmax = 1.14 ± 0.12 μg/g, tmax = 1 h).",Nose to brain delivery of tailored clozapine nanosuspension stabilized using (+)-alpha-tocopherol polyethylene glycol 1000 succinate: Optimization and in vivo pharmacokinetic studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33737093/),h,1,85287,DB00363,Clozapine
,33737093,Cmax,"The single-dose in vivo pharmacokinetic analysis in the rat model showed a substantial increase in the therapeutic concentration of clozapine in the brain tissue in the case of intranasal nanosuspension (dose = 0.05 mg drug/0.1 mL, Cmax = 8.62 ± 0.45 μg/g, tmax = 1 h) compared to conventional oral clozapine suspension (dose = 26.43 mg drug/0.158 mL, Cmax = 1.14 ± 0.12 μg/g, tmax = 1 h).",Nose to brain delivery of tailored clozapine nanosuspension stabilized using (+)-alpha-tocopherol polyethylene glycol 1000 succinate: Optimization and in vivo pharmacokinetic studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33737093/),[μg] / [g],1.14,85288,DB00363,Clozapine
,19194306,metabolic ratio,"The metabolic ratio of the good responders was 0.65+/-0.20, higher than the poor responders (P=0.033).",Determination of pharmacokinetic properties of clozapine and norclozapine in Korean schizophrenia patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19194306/),,0.65,85289,DB00363,Clozapine
,8458896,limits of detection,"The limits of detection for clozapine and desmethylclozapine are 2 and 1 ng/ml, respectively.",Determination of clozapine and desmethylclozapine in human plasma by high-performance liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8458896/),[ng] / [ml],2,91104,DB00363,Clozapine
,8458896,limits of detection,"The limits of detection for clozapine and desmethylclozapine are 2 and 1 ng/ml, respectively.",Determination of clozapine and desmethylclozapine in human plasma by high-performance liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8458896/),[ng] / [ml],1,91105,DB00363,Clozapine
,15018785,flow-rate,"The HPLC separation of the analytes was performed on a MACHEREY-NAGEL C(18) (2.0 mm x 125 mm, 3 microm, Germany) column, using water (formic acid: 2.70 mmol/l, ammonium acetate: 10 mmol/l)-acetonitrile (53:47) as mobile phase, with a flow-rate of 0.16 ml/min.","Simultaneous determination of clozapine, olanzapine, risperidone and quetiapine in plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15018785/),[ml] / [min],0.16,91882,DB00363,Clozapine
above,15018785,extraction recoveries,The average extraction recoveries for all the four analysts were at least above 80%.,"Simultaneous determination of clozapine, olanzapine, risperidone and quetiapine in plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15018785/),%,80,91883,DB00363,Clozapine
higher,15018785,recoveries,The methodology recoveries were higher than 91% for the analysts.,"Simultaneous determination of clozapine, olanzapine, risperidone and quetiapine in plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15018785/),%,91,91884,DB00363,Clozapine
,17230450,flow rate,"The mobile phase was methanol-water containing 10 mmol/L ammonium acetate, pH 7.9 adjusted with aqueous ammonia (80:20, v/v) at the flow rate of 1.0 mL/min.",Liquid chromatography-mass spectrometry method for the determination of venlafaxine in human plasma and application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17230450/),[ml] / [min],1.0,97411,DB00363,Clozapine
,17230450,Relative bioavailability,Relative bioavailability was 103.4 +/- 14.1%.,Liquid chromatography-mass spectrometry method for the determination of venlafaxine in human plasma and application to a pharmacokinetic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17230450/),%,103.4,97412,DB00363,Clozapine
,34142950,AUC0-12,"The mean AUC0-12 was 6,003.29 h×ng/mL for generic clozapine and 6,347.53 h×ng/mL for Clozaril.","Evaluation of bioequivalence between generic and brand-name clozapine in Chinese schizophrenic patients: A randomized, two-period, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34142950/),[h·ng] / [ml],"6,003.29",98434,DB00363,Clozapine
,34142950,AUC0-12,"The mean AUC0-12 was 6,003.29 h×ng/mL for generic clozapine and 6,347.53 h×ng/mL for Clozaril.","Evaluation of bioequivalence between generic and brand-name clozapine in Chinese schizophrenic patients: A randomized, two-period, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34142950/),[h·ng] / [ml],"6,347.53",98435,DB00363,Clozapine
,34142950,"Cmax,ss","The mean Cmax,ss was 698.52 ng/mL for generic clozapine and 739.75 ng/mL for Clozaril.","Evaluation of bioequivalence between generic and brand-name clozapine in Chinese schizophrenic patients: A randomized, two-period, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34142950/),[ng] / [ml],698.52,98436,DB00363,Clozapine
,34142950,"Cmax,ss","The mean Cmax,ss was 698.52 ng/mL for generic clozapine and 739.75 ng/mL for Clozaril.","Evaluation of bioequivalence between generic and brand-name clozapine in Chinese schizophrenic patients: A randomized, two-period, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34142950/),[ng] / [ml],739.75,98437,DB00363,Clozapine
,12562141,terminal half-life,"In humans, quetiapine exhibits linear pharmacokinetics with a mean terminal half-life of 7 hours.","Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12562141/),h,7,99732,DB00363,Clozapine
,9829293,serum concentrations,3. Mean serum concentrations were 8 ng/ml for haloperidol and 21 ng/ml for clozapine.,"Chronical haloperidol and clozapine treatment in rats: differential RNA display analysis, behavioral studies and serum level determination. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9829293/),[ng] / [ml],8,100928,DB00363,Clozapine
,9829293,serum concentrations,3. Mean serum concentrations were 8 ng/ml for haloperidol and 21 ng/ml for clozapine.,"Chronical haloperidol and clozapine treatment in rats: differential RNA display analysis, behavioral studies and serum level determination. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9829293/),[ng] / [ml],21,100929,DB00363,Clozapine
,3508549,half-life,"The terminal elimination appeared to follow linear kinetics and had a mean half-life of 15.8 hr (range, 5.8-33 hr).",Multiple-dose pharmacokinetics of clozapine in patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3508549/),h,15.8,102266,DB00363,Clozapine
,26079968,elimination rate constant,"When the reported toxic dosage was 3,740 mg, the elimination rate constant of the population was 0.0258(h(-1)).",The Elimination Rate after Clozapine Overdose in Chinese Schizophrenia Patients: A Population Pharmacokinetics Model Study. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26079968/),1/[h],0.0258,103245,DB00363,Clozapine
,26079968,elimination half-life,The elimination half-life was 26.9 h.,The Elimination Rate after Clozapine Overdose in Chinese Schizophrenia Patients: A Population Pharmacokinetics Model Study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26079968/),h,26.9,103246,DB00363,Clozapine
,26207129,"Cmax,ss","The mean Cmax,ss values for Clzapine and Clozaril were 524.62 and 551.18 ng/mL, and the mean AUC0-12 values were 4479.90 hr·ng/mL and 4724.56 hr·ng/mL, respectively.","Bioequivalence of Generic and Brand Name Clozapine in Korean Schizophrenic Patients: A Randomized, Two-Period, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26207129/),[ng] / [ml],524.62,104116,DB00363,Clozapine
,26207129,"Cmax,ss","The mean Cmax,ss values for Clzapine and Clozaril were 524.62 and 551.18 ng/mL, and the mean AUC0-12 values were 4479.90 hr·ng/mL and 4724.56 hr·ng/mL, respectively.","Bioequivalence of Generic and Brand Name Clozapine in Korean Schizophrenic Patients: A Randomized, Two-Period, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26207129/),[ng] / [ml],551.18,104117,DB00363,Clozapine
,26207129,AUC0-12,"The mean Cmax,ss values for Clzapine and Clozaril were 524.62 and 551.18 ng/mL, and the mean AUC0-12 values were 4479.90 hr·ng/mL and 4724.56 hr·ng/mL, respectively.","Bioequivalence of Generic and Brand Name Clozapine in Korean Schizophrenic Patients: A Randomized, Two-Period, Crossover Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26207129/),[h·ng] / [ml],4479.90,104118,DB00363,Clozapine
,26207129,AUC0-12,"The mean Cmax,ss values for Clzapine and Clozaril were 524.62 and 551.18 ng/mL, and the mean AUC0-12 values were 4479.90 hr·ng/mL and 4724.56 hr·ng/mL, respectively.","Bioequivalence of Generic and Brand Name Clozapine in Korean Schizophrenic Patients: A Randomized, Two-Period, Crossover Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26207129/),[h·ng] / [ml],4724.56,104119,DB00363,Clozapine
,11076069,flow-rate,"The mobile phase consisted of phosphate buffer (0.05 M, pH 3.7 with 25% H3PO4)-acetonitrile (70:30, v/v), and was delivered at a flow-rate of 1.0 ml/min.",Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11076069/),[ml] / [min],1.0,111533,DB00363,Clozapine
,11076069,total time,The peaks were detected using a UV detector set at 278 nm and the total time for a chromatographic separation was about 4 min.,Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11076069/),min,4,111534,DB00363,Clozapine
,11076069,recoveries,Mean recoveries were 98.0% for risperidone and 83.5% for 9-hydroxyrisperidone.,Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11076069/),%,98.0,111535,DB00363,Clozapine
,11076069,recoveries,Mean recoveries were 98.0% for risperidone and 83.5% for 9-hydroxyrisperidone.,Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11076069/),%,83.5,111536,DB00363,Clozapine
,7767316,half-life,"The in vivo biodistribution of this novel radioligand in mice showed a high uptake in the striatum (6.7% ID/g) at 5 min, followed by clearance with a half-life of 16.1 min.",[11C]A-69024: a potent and selective non-benzazepine radiotracer for in vivo studies of dopamine D1 receptors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7767316/),min,16.1,112974,DB00363,Clozapine
,7767316,ratio,"As a measure of specificity, the striatal/cerebellar ratio reached a maximum of 7.4 at 30 min post-injection.",[11C]A-69024: a potent and selective non-benzazepine radiotracer for in vivo studies of dopamine D1 receptors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7767316/),,7.4,112975,DB00363,Clozapine
,7767316,ED50,[11C]A-69024 binding was inhibited by unlabeled A-69024 in a dose dependent manner (ED50 = 0.3 mg/kg) in the striatum while no change occurred in the cerebellum.,[11C]A-69024: a potent and selective non-benzazepine radiotracer for in vivo studies of dopamine D1 receptors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7767316/),[mg] / [kg],0.3,112976,DB00363,Clozapine
,15538130,half-life,"In normal subjects after a single oral dose, haloperidol half-life has been reported to range 14.5-36.7 hours (or up to 1.5 days).",Haloperidol half-life after chronic dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15538130/),h,14.5-36.7,112987,DB00363,Clozapine
up to,15538130,half-life,"In normal subjects after a single oral dose, haloperidol half-life has been reported to range 14.5-36.7 hours (or up to 1.5 days).",Haloperidol half-life after chronic dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15538130/),d,1.5,112988,DB00363,Clozapine
up to,15538130,half-lives,"After chronic administration, half-lives of up to 21 days have been reported.",Haloperidol half-life after chronic dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15538130/),d,21,112989,DB00363,Clozapine
,15538130,half-life,"The geometric mean for haloperidol half-life and detectable levels duration were 3.9 and 13.8 days, respectively.",Haloperidol half-life after chronic dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15538130/),d,3.9,112990,DB00363,Clozapine
,15538130,detectable levels duration,"The geometric mean for haloperidol half-life and detectable levels duration were 3.9 and 13.8 days, respectively.",Haloperidol half-life after chronic dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15538130/),d,13.8,112991,DB00363,Clozapine
<,15538130,half-lives,"Within 31 subjects, 58% (18/31) had half-lives <3 days (1.2-2.3 days) and 42% (13/31) had half-lives > or =3 days.",Haloperidol half-life after chronic dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15538130/),d,3,112992,DB00363,Clozapine
> or =,15538130,half-lives,"Within 31 subjects, 58% (18/31) had half-lives <3 days (1.2-2.3 days) and 42% (13/31) had half-lives > or =3 days.",Haloperidol half-life after chronic dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15538130/),d,3,112993,DB00363,Clozapine
longer,15538130,half-lives,Two of 3 patients with half-lives longer than 30 days (720 hours) and levels detectable >2 months had received haloperidol decanoate.,Haloperidol half-life after chronic dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15538130/),d,30,112994,DB00363,Clozapine
>,15538130,half-lives,"Five patients who received haloperidol decanoate in the prior year were excluded from a comparison between patients with long haloperidol half-lives (> or =3 days, n = 10) and patients with short half-lives (<3 days, n = 16).",Haloperidol half-life after chronic dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15538130/),d,or,112995,DB00363,Clozapine
>,15538130,half-lives,"Five patients who received haloperidol decanoate in the prior year were excluded from a comparison between patients with long haloperidol half-lives (> or =3 days, n = 10) and patients with short half-lives (<3 days, n = 16).",Haloperidol half-life after chronic dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15538130/),d,3,112996,DB00363,Clozapine
<,15538130,half-lives,"Five patients who received haloperidol decanoate in the prior year were excluded from a comparison between patients with long haloperidol half-lives (> or =3 days, n = 10) and patients with short half-lives (<3 days, n = 16).",Haloperidol half-life after chronic dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15538130/),d,3,112997,DB00363,Clozapine
> or =,15538130,half-lives,CYP3A5 genotype did not appear to influence haloperidol half-life but the two CYP2D6 poor metabolizer had half-lives > or =3 days.,Haloperidol half-life after chronic dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15538130/),d,3,112998,DB00363,Clozapine
,9497016,plasma half-life,Quetiapine (Seroquel) is a novel antipsychotic with an atypical profile in animal models and a relatively short plasma half-life of 2.5 5 h.,Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9497016/),h,2.5,114312,DB00363,Clozapine
,9497016,t[max],"Quetiapine was shown to bind to dopamine D2 receptors in striatum and 2 h (t[max]) after the last dose, 44% receptor occupancy was calculated.",Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9497016/),h,2,114313,DB00363,Clozapine
,9497016,t[max],"Quetiapine was shown to bind to dopamine D2 receptors in striatum and 2 h (t[max]) after the last dose, 44% receptor occupancy was calculated.",Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9497016/),%,44,114314,DB00363,Clozapine
,9497016,terminal plasma half-life,The terminal plasma half-life of quetiapine was 5.3 h.,Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9497016/),h,5.3,114315,DB00363,Clozapine
,9497016,occupancy half-life,"Our data shows that quetiapine has a relatively low affinity for dopamine D2 receptors, with an occupancy half-life (10 h), which was about twice as long as that for plasma.",Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9497016/),h,10,114316,DB00363,Clozapine
,9497016,receptor occupancy half-life,"A more prolonged blockade of the serotonin 5HT2 receptors was found in the frontal cortex, with receptor occupancy half-life of 27 h.",Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9497016/),h,27,114317,DB00363,Clozapine
,2194198,t1/2 m3,"In contrast, the terminal elimination rate differed between the single-dose and the multiple-dose treatments (t1/2 m3 = 7.9 hr single dose and 14.2 hr multiple dose) (P less than 0.05) and the dose-normalized area under the plasma concentration/time curves increased 27% with multiple dosing.",Single- vs multiple-dose pharmacokinetics of clozapine in psychiatric patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2194198/),h,7.9,117464,DB00363,Clozapine
,2194198,t1/2 m3,"In contrast, the terminal elimination rate differed between the single-dose and the multiple-dose treatments (t1/2 m3 = 7.9 hr single dose and 14.2 hr multiple dose) (P less than 0.05) and the dose-normalized area under the plasma concentration/time curves increased 27% with multiple dosing.",Single- vs multiple-dose pharmacokinetics of clozapine in psychiatric patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2194198/),h,14.2,117465,DB00363,Clozapine
,22820910,clearance,"The population-predicted clearance of clozapine and norclozapine in female nonsmokers were 21.9 and 32.7 L/h, respectively.",Population pharmacokinetics of clozapine and its primary metabolite norclozapine in Chinese patients with schizophrenia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22820910/),[l] / [h],21.9,121740,DB00363,Clozapine
,22820910,clearance,"The population-predicted clearance of clozapine and norclozapine in female nonsmokers were 21.9 and 32.7 L/h, respectively.",Population pharmacokinetics of clozapine and its primary metabolite norclozapine in Chinese patients with schizophrenia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22820910/),[l] / [h],32.7,121741,DB00363,Clozapine
,22820910,volumes of distribution,"The population-predicted volumes of distribution for clozapine and norclozapine were 526 and 624 L, respectively.",Population pharmacokinetics of clozapine and its primary metabolite norclozapine in Chinese patients with schizophrenia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22820910/),l,526,121742,DB00363,Clozapine
,22820910,volumes of distribution,"The population-predicted volumes of distribution for clozapine and norclozapine were 526 and 624 L, respectively.",Population pharmacokinetics of clozapine and its primary metabolite norclozapine in Chinese patients with schizophrenia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22820910/),l,624,121743,DB00363,Clozapine
,9833598,unbound fractions,"The following unbound fractions in serum were found (geometric means): clozapine 5.5%, N-desmethylclozapine 9.7%, and clozapine N-oxide 24.6%.",Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9833598/),%,5.5,124387,DB00363,Clozapine
,9833598,unbound fractions,"The following unbound fractions in serum were found (geometric means): clozapine 5.5%, N-desmethylclozapine 9.7%, and clozapine N-oxide 24.6%.",Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9833598/),%,9.7,124388,DB00363,Clozapine
,9833598,unbound fractions,"The following unbound fractions in serum were found (geometric means): clozapine 5.5%, N-desmethylclozapine 9.7%, and clozapine N-oxide 24.6%.",Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9833598/),%,24.6,124389,DB00363,Clozapine
,31976069,plasma level,Overall mean standardized clozapine plasma level was 0.67 mg/l daily dose on liquid and 0.87 mg/l daily dose on tablets (p = 0.035).,Change in plasma concentration of clozapine and norclozapine following a switch of oral formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31976069/),[mg] / [l],0.67,128404,DB00363,Clozapine
,31976069,plasma level,Overall mean standardized clozapine plasma level was 0.67 mg/l daily dose on liquid and 0.87 mg/l daily dose on tablets (p = 0.035).,Change in plasma concentration of clozapine and norclozapine following a switch of oral formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31976069/),[mg] / [l],0.87,128405,DB00363,Clozapine
,10379638,area under the serum concentration time curves,"There were no significant differences in mean area under the serum concentration time curves (1348 (633) nmol h x l(-1) in the control phase and 1180 (659) nmol h x l(-1) in the erythromycin phase), terminal halflives (19 (13) h and 15 (6) h, respectively), peak serum concentrations (92 (53) nmol x l(-1) and 77 (40) nmol x l(-1), respectively), time to peak serum concentrations (1.4 (0.7) h and 1.5 (1.0) h, respectively) or apparent oral clearances of clozapine (34 (15) l x h(-1) and 46 (37) l x h(-1), respectively).",Absence of interaction between erythromycin and a single dose of clozapine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379638/),[h·nM] / [l],1348,130505,DB00363,Clozapine
,10379638,area under the serum concentration time curves,"There were no significant differences in mean area under the serum concentration time curves (1348 (633) nmol h x l(-1) in the control phase and 1180 (659) nmol h x l(-1) in the erythromycin phase), terminal halflives (19 (13) h and 15 (6) h, respectively), peak serum concentrations (92 (53) nmol x l(-1) and 77 (40) nmol x l(-1), respectively), time to peak serum concentrations (1.4 (0.7) h and 1.5 (1.0) h, respectively) or apparent oral clearances of clozapine (34 (15) l x h(-1) and 46 (37) l x h(-1), respectively).",Absence of interaction between erythromycin and a single dose of clozapine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379638/),[h·nM] / [l],1180,130506,DB00363,Clozapine
,10379638,terminal halflives,"There were no significant differences in mean area under the serum concentration time curves (1348 (633) nmol h x l(-1) in the control phase and 1180 (659) nmol h x l(-1) in the erythromycin phase), terminal halflives (19 (13) h and 15 (6) h, respectively), peak serum concentrations (92 (53) nmol x l(-1) and 77 (40) nmol x l(-1), respectively), time to peak serum concentrations (1.4 (0.7) h and 1.5 (1.0) h, respectively) or apparent oral clearances of clozapine (34 (15) l x h(-1) and 46 (37) l x h(-1), respectively).",Absence of interaction between erythromycin and a single dose of clozapine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379638/),h,19,130507,DB00363,Clozapine
,10379638,terminal halflives,"There were no significant differences in mean area under the serum concentration time curves (1348 (633) nmol h x l(-1) in the control phase and 1180 (659) nmol h x l(-1) in the erythromycin phase), terminal halflives (19 (13) h and 15 (6) h, respectively), peak serum concentrations (92 (53) nmol x l(-1) and 77 (40) nmol x l(-1), respectively), time to peak serum concentrations (1.4 (0.7) h and 1.5 (1.0) h, respectively) or apparent oral clearances of clozapine (34 (15) l x h(-1) and 46 (37) l x h(-1), respectively).",Absence of interaction between erythromycin and a single dose of clozapine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379638/),h,15,130508,DB00363,Clozapine
,10379638,peak serum concentrations,"There were no significant differences in mean area under the serum concentration time curves (1348 (633) nmol h x l(-1) in the control phase and 1180 (659) nmol h x l(-1) in the erythromycin phase), terminal halflives (19 (13) h and 15 (6) h, respectively), peak serum concentrations (92 (53) nmol x l(-1) and 77 (40) nmol x l(-1), respectively), time to peak serum concentrations (1.4 (0.7) h and 1.5 (1.0) h, respectively) or apparent oral clearances of clozapine (34 (15) l x h(-1) and 46 (37) l x h(-1), respectively).",Absence of interaction between erythromycin and a single dose of clozapine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379638/),[nM] / [l],92,130509,DB00363,Clozapine
,10379638,peak serum concentrations,"There were no significant differences in mean area under the serum concentration time curves (1348 (633) nmol h x l(-1) in the control phase and 1180 (659) nmol h x l(-1) in the erythromycin phase), terminal halflives (19 (13) h and 15 (6) h, respectively), peak serum concentrations (92 (53) nmol x l(-1) and 77 (40) nmol x l(-1), respectively), time to peak serum concentrations (1.4 (0.7) h and 1.5 (1.0) h, respectively) or apparent oral clearances of clozapine (34 (15) l x h(-1) and 46 (37) l x h(-1), respectively).",Absence of interaction between erythromycin and a single dose of clozapine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379638/),[nM] / [l],77,130510,DB00363,Clozapine
,10379638,time to peak serum concentrations,"There were no significant differences in mean area under the serum concentration time curves (1348 (633) nmol h x l(-1) in the control phase and 1180 (659) nmol h x l(-1) in the erythromycin phase), terminal halflives (19 (13) h and 15 (6) h, respectively), peak serum concentrations (92 (53) nmol x l(-1) and 77 (40) nmol x l(-1), respectively), time to peak serum concentrations (1.4 (0.7) h and 1.5 (1.0) h, respectively) or apparent oral clearances of clozapine (34 (15) l x h(-1) and 46 (37) l x h(-1), respectively).",Absence of interaction between erythromycin and a single dose of clozapine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379638/),h,1.4,130511,DB00363,Clozapine
,10379638,time to peak serum concentrations,"There were no significant differences in mean area under the serum concentration time curves (1348 (633) nmol h x l(-1) in the control phase and 1180 (659) nmol h x l(-1) in the erythromycin phase), terminal halflives (19 (13) h and 15 (6) h, respectively), peak serum concentrations (92 (53) nmol x l(-1) and 77 (40) nmol x l(-1), respectively), time to peak serum concentrations (1.4 (0.7) h and 1.5 (1.0) h, respectively) or apparent oral clearances of clozapine (34 (15) l x h(-1) and 46 (37) l x h(-1), respectively).",Absence of interaction between erythromycin and a single dose of clozapine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379638/),h,1.5,130512,DB00363,Clozapine
,10379638,apparent oral clearances,"There were no significant differences in mean area under the serum concentration time curves (1348 (633) nmol h x l(-1) in the control phase and 1180 (659) nmol h x l(-1) in the erythromycin phase), terminal halflives (19 (13) h and 15 (6) h, respectively), peak serum concentrations (92 (53) nmol x l(-1) and 77 (40) nmol x l(-1), respectively), time to peak serum concentrations (1.4 (0.7) h and 1.5 (1.0) h, respectively) or apparent oral clearances of clozapine (34 (15) l x h(-1) and 46 (37) l x h(-1), respectively).",Absence of interaction between erythromycin and a single dose of clozapine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379638/),[l] / [h],34,130513,DB00363,Clozapine
,10379638,apparent oral clearances,"There were no significant differences in mean area under the serum concentration time curves (1348 (633) nmol h x l(-1) in the control phase and 1180 (659) nmol h x l(-1) in the erythromycin phase), terminal halflives (19 (13) h and 15 (6) h, respectively), peak serum concentrations (92 (53) nmol x l(-1) and 77 (40) nmol x l(-1), respectively), time to peak serum concentrations (1.4 (0.7) h and 1.5 (1.0) h, respectively) or apparent oral clearances of clozapine (34 (15) l x h(-1) and 46 (37) l x h(-1), respectively).",Absence of interaction between erythromycin and a single dose of clozapine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379638/),[l] / [h],46,130514,DB00363,Clozapine
,10379638,partial metabolic clearances,"There were no significant differences in partial metabolic clearances to clozapine-N-oxide (5.1 (3.6) l x h(-1) and 7.8 (9.4) l x h(-1), respectively) or to desmethyl-clozapine (1.5 (1.3) l x h(-1) and 1.8 (1.7) l x h(-1), respectively) or in renal clearances of clozapine (0.8 (0.5) l x h(-1) and 1.0 (0.7) l x h(-1), respectively) between the two phases.",Absence of interaction between erythromycin and a single dose of clozapine. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379638/),[l] / [h],5.1,130515,DB00363,Clozapine
,10379638,partial metabolic clearances,"There were no significant differences in partial metabolic clearances to clozapine-N-oxide (5.1 (3.6) l x h(-1) and 7.8 (9.4) l x h(-1), respectively) or to desmethyl-clozapine (1.5 (1.3) l x h(-1) and 1.8 (1.7) l x h(-1), respectively) or in renal clearances of clozapine (0.8 (0.5) l x h(-1) and 1.0 (0.7) l x h(-1), respectively) between the two phases.",Absence of interaction between erythromycin and a single dose of clozapine. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379638/),[l] / [h],7.8,130516,DB00363,Clozapine
,10379638,partial metabolic clearances,"There were no significant differences in partial metabolic clearances to clozapine-N-oxide (5.1 (3.6) l x h(-1) and 7.8 (9.4) l x h(-1), respectively) or to desmethyl-clozapine (1.5 (1.3) l x h(-1) and 1.8 (1.7) l x h(-1), respectively) or in renal clearances of clozapine (0.8 (0.5) l x h(-1) and 1.0 (0.7) l x h(-1), respectively) between the two phases.",Absence of interaction between erythromycin and a single dose of clozapine. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379638/),[l] / [h],1.5,130517,DB00363,Clozapine
,10379638,partial metabolic clearances,"There were no significant differences in partial metabolic clearances to clozapine-N-oxide (5.1 (3.6) l x h(-1) and 7.8 (9.4) l x h(-1), respectively) or to desmethyl-clozapine (1.5 (1.3) l x h(-1) and 1.8 (1.7) l x h(-1), respectively) or in renal clearances of clozapine (0.8 (0.5) l x h(-1) and 1.0 (0.7) l x h(-1), respectively) between the two phases.",Absence of interaction between erythromycin and a single dose of clozapine. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379638/),[l] / [h],1.8,130518,DB00363,Clozapine
,10379638,renal clearances,"There were no significant differences in partial metabolic clearances to clozapine-N-oxide (5.1 (3.6) l x h(-1) and 7.8 (9.4) l x h(-1), respectively) or to desmethyl-clozapine (1.5 (1.3) l x h(-1) and 1.8 (1.7) l x h(-1), respectively) or in renal clearances of clozapine (0.8 (0.5) l x h(-1) and 1.0 (0.7) l x h(-1), respectively) between the two phases.",Absence of interaction between erythromycin and a single dose of clozapine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379638/),[l] / [h],0.8,130519,DB00363,Clozapine
,10379638,renal clearances,"There were no significant differences in partial metabolic clearances to clozapine-N-oxide (5.1 (3.6) l x h(-1) and 7.8 (9.4) l x h(-1), respectively) or to desmethyl-clozapine (1.5 (1.3) l x h(-1) and 1.8 (1.7) l x h(-1), respectively) or in renal clearances of clozapine (0.8 (0.5) l x h(-1) and 1.0 (0.7) l x h(-1), respectively) between the two phases.",Absence of interaction between erythromycin and a single dose of clozapine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10379638/),[l] / [h],1.0,130520,DB00363,Clozapine
,9949479,peak serum concentration,"To detect and quantify clozapine in plasma, high-pressure liquid chromatography showed a 4 h absorption phase and a peak serum concentration of 5200 ng/ml.",Non-fatal clozapine (LEPONEX) intoxication with toxicokinetic evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9949479/),[ng] / [ml],5200,132409,DB00363,Clozapine
,9949479,elimination t1/2,"Three successive elimination t1/2 values of 38, 24 and 13 h were calculated.",Non-fatal clozapine (LEPONEX) intoxication with toxicokinetic evaluation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9949479/),h,38,132410,DB00363,Clozapine
,9949479,elimination t1/2,"Three successive elimination t1/2 values of 38, 24 and 13 h were calculated.",Non-fatal clozapine (LEPONEX) intoxication with toxicokinetic evaluation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9949479/),h,24,132411,DB00363,Clozapine
,9949479,elimination t1/2,"Three successive elimination t1/2 values of 38, 24 and 13 h were calculated.",Non-fatal clozapine (LEPONEX) intoxication with toxicokinetic evaluation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9949479/),h,13,132412,DB00363,Clozapine
,32518001,C/D ratio,"The median C/D ratio in our sample was 2.5 (n = 142), and the clozapine dose needed to achieve therapeutic serum clozapine level was 140 mg/d.",Do Indian patients with schizophrenia need half the recommended clozapine dose to achieve therapeutic serum level? An exploratory study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32518001/),,2.5,132891,DB00363,Clozapine
,32518001,C/D ratio,The median C/D ratio of our subjects was nearly two and a half times higher than the weighted mean C/D ratio of Caucasians (2.5 v/s 1.07) reported elsewhere.,Do Indian patients with schizophrenia need half the recommended clozapine dose to achieve therapeutic serum level? An exploratory study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32518001/),,2.5,132892,DB00363,Clozapine
,32518001,C/D ratio,"After excluding the significant pharmacokinetic interactions and stratifying according to gender and smoking status, the estimated clozapine dose to achieve therapeutic serum level in male smokers (n = 9) and female non-smokers (n = 38) were 238 mg/d (C/D ratio; 1.47) and 120 mg/d (C/D ratio:2.93) respectively.",Do Indian patients with schizophrenia need half the recommended clozapine dose to achieve therapeutic serum level? An exploratory study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32518001/),,1.47,132893,DB00363,Clozapine
,32518001,C/D ratio,"After excluding the significant pharmacokinetic interactions and stratifying according to gender and smoking status, the estimated clozapine dose to achieve therapeutic serum level in male smokers (n = 9) and female non-smokers (n = 38) were 238 mg/d (C/D ratio; 1.47) and 120 mg/d (C/D ratio:2.93) respectively.",Do Indian patients with schizophrenia need half the recommended clozapine dose to achieve therapeutic serum level? An exploratory study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32518001/),,120,132894,DB00363,Clozapine
,32518001,C/D ratio,"After excluding the significant pharmacokinetic interactions and stratifying according to gender and smoking status, the estimated clozapine dose to achieve therapeutic serum level in male smokers (n = 9) and female non-smokers (n = 38) were 238 mg/d (C/D ratio; 1.47) and 120 mg/d (C/D ratio:2.93) respectively.",Do Indian patients with schizophrenia need half the recommended clozapine dose to achieve therapeutic serum level? An exploratory study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32518001/),,2.93,132895,DB00363,Clozapine
exceeded,8353952,Absolute recovery,"Absolute recovery exceeded 65%, and the detection limit was approximately 3-4 micrograms/L.","Determination of clozapine, norclozapine, and clozapine-N-oxide in serum by liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8353952/),%,65,138577,DB00363,Clozapine
,8353952,detection limit,"Absolute recovery exceeded 65%, and the detection limit was approximately 3-4 micrograms/L.","Determination of clozapine, norclozapine, and clozapine-N-oxide in serum by liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8353952/),[μg] / [l],3-4,138578,DB00363,Clozapine
,30872749,half maximal effective concentration (EC50),The half maximal effective concentration (EC50) of CLZ was substantially lower (0.42 nM) than CNO (8.1 nM); Cmpd-21 was intermediate (2.95 nM).,"Pharmacokinetic and pharmacodynamic actions of clozapine-N-oxide, clozapine, and compound 21 in DREADD-based chemogenetics in mice. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30872749/),nM,0.42,139580,DB00363,Clozapine
,30872749,half maximal effective concentration (EC50),The half maximal effective concentration (EC50) of CLZ was substantially lower (0.42 nM) than CNO (8.1 nM); Cmpd-21 was intermediate (2.95 nM).,"Pharmacokinetic and pharmacodynamic actions of clozapine-N-oxide, clozapine, and compound 21 in DREADD-based chemogenetics in mice. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30872749/),nM,8.1,139581,DB00363,Clozapine
,30872749,half maximal effective concentration (EC50),The half maximal effective concentration (EC50) of CLZ was substantially lower (0.42 nM) than CNO (8.1 nM); Cmpd-21 was intermediate (2.95 nM).,"Pharmacokinetic and pharmacodynamic actions of clozapine-N-oxide, clozapine, and compound 21 in DREADD-based chemogenetics in mice. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30872749/),nM,2.95,139582,DB00363,Clozapine
,9868741,limit of detection,The limit of detection was 0.06 nmol.mg protein-1.hr-1.,Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868741/),[-1·mg·nM] / [h],0.06,140625,DB00363,Clozapine
,9868741,Ki,"As expected, fluvoxamine was a very potent inhibitor of the formation of the N-demethylated caffeine metabolites, displaying Ki values of 0.08-0.28 microM.",Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868741/),μM,0.08-0.28,140626,DB00363,Clozapine
,9868741,Kis,"The CYP3A4 inhibitors, ketoconazole and bromocriptine, inhibited 1,3,7-trimethyluric acid formation with Kis of 0.75 microM and 5 microM, respectively, thus further supporting the involvement of CYP3A4 in the 8-hydroxylation of caffeine.",Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868741/),μM,0.75,140627,DB00363,Clozapine
,9868741,Kis,"The CYP3A4 inhibitors, ketoconazole and bromocriptine, inhibited 1,3,7-trimethyluric acid formation with Kis of 0.75 microM and 5 microM, respectively, thus further supporting the involvement of CYP3A4 in the 8-hydroxylation of caffeine.",Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868741/),μM,5,140628,DB00363,Clozapine
<,16014318,oral bioavailability,"Clozapine, a lipophilic effective atypical antipsychotic drug, has very poor oral bioavailability (<27%) due to first pass effect.","Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16014318/),%,27,141602,DB00363,Clozapine
,16014318,size,"Average size and zeta potential of SLNs of different lipids with stearylamine ranged from 96.7+/-3.8 to 163.3+/-0.7 nm and 21.3+/-1.3 to 33.2+/-0.6 mV, respectively.","Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16014318/),nm,96.7,141603,DB00363,Clozapine
,16014318,size,"Average size and zeta potential of SLNs of different lipids with stearylamine ranged from 96.7+/-3.8 to 163.3+/-0.7 nm and 21.3+/-1.3 to 33.2+/-0.6 mV, respectively.","Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16014318/),nm,163.3,141604,DB00363,Clozapine
,16014318,zeta potential,"Average size and zeta potential of SLNs of different lipids with stearylamine ranged from 96.7+/-3.8 to 163.3+/-0.7 nm and 21.3+/-1.3 to 33.2+/-0.6 mV, respectively.","Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16014318/),nm,163.3,141605,DB00363,Clozapine
,16014318,zeta potential,"Average size and zeta potential of SLNs of different lipids with stearylamine ranged from 96.7+/-3.8 to 163.3+/-0.7 nm and 21.3+/-1.3 to 33.2+/-0.6 mV, respectively.","Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16014318/),mv,21.3,141606,DB00363,Clozapine
,16014318,zeta potential,"Average size and zeta potential of SLNs of different lipids with stearylamine ranged from 96.7+/-3.8 to 163.3+/-0.7 nm and 21.3+/-1.3 to 33.2+/-0.6 mV, respectively.","Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16014318/),mv,33.2,141607,DB00363,Clozapine
,2682731,halflife time,Acute pharmacokinetic data showed a wide interindividual range with a mean halflife time of 6.0 h.,Clozapine--pharmacokinetic investigations and biochemical effects in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2682731/),h,6.0,145385,DB00363,Clozapine
,26129833,flow rate,The analytes were chromatographed on a Waters Acquity H class UPLC system using isocratic mobile phase conditions at a flow rate of 0.3 mL/min and Acquity UPLC BEH shield RP18 column maintained at 40°C.,"Concurrent determination of olanzapine, risperidone and 9-hydroxyrisperidone in human plasma by ultra performance liquid chromatography with diode array detection method: application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26129833/),[ml] / [min],0.3,153465,DB00363,Clozapine
,26129833,retention times,"OLZ, RIS, 9-OHRIS and IS retention times were found to be 0.9, 1.4, .1.8 and 3.1 min, respectively, and the total run time was 4 min.","Concurrent determination of olanzapine, risperidone and 9-hydroxyrisperidone in human plasma by ultra performance liquid chromatography with diode array detection method: application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26129833/),min,0.9,153466,DB00363,Clozapine
,26129833,retention times,"OLZ, RIS, 9-OHRIS and IS retention times were found to be 0.9, 1.4, .1.8 and 3.1 min, respectively, and the total run time was 4 min.","Concurrent determination of olanzapine, risperidone and 9-hydroxyrisperidone in human plasma by ultra performance liquid chromatography with diode array detection method: application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26129833/),min,1.4,153467,DB00363,Clozapine
,26129833,retention times,"OLZ, RIS, 9-OHRIS and IS retention times were found to be 0.9, 1.4, .1.8 and 3.1 min, respectively, and the total run time was 4 min.","Concurrent determination of olanzapine, risperidone and 9-hydroxyrisperidone in human plasma by ultra performance liquid chromatography with diode array detection method: application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26129833/),min,.,153468,DB00363,Clozapine
,26129833,retention times,"OLZ, RIS, 9-OHRIS and IS retention times were found to be 0.9, 1.4, .1.8 and 3.1 min, respectively, and the total run time was 4 min.","Concurrent determination of olanzapine, risperidone and 9-hydroxyrisperidone in human plasma by ultra performance liquid chromatography with diode array detection method: application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26129833/),min,1.8,153469,DB00363,Clozapine
,26129833,retention times,"OLZ, RIS, 9-OHRIS and IS retention times were found to be 0.9, 1.4, .1.8 and 3.1 min, respectively, and the total run time was 4 min.","Concurrent determination of olanzapine, risperidone and 9-hydroxyrisperidone in human plasma by ultra performance liquid chromatography with diode array detection method: application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26129833/),min,3.1,153470,DB00363,Clozapine
,26129833,total run time,"OLZ, RIS, 9-OHRIS and IS retention times were found to be 0.9, 1.4, .1.8 and 3.1 min, respectively, and the total run time was 4 min.","Concurrent determination of olanzapine, risperidone and 9-hydroxyrisperidone in human plasma by ultra performance liquid chromatography with diode array detection method: application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26129833/),min,4,153471,DB00363,Clozapine
,9472836,elimination half-life,Estimation of the mean elimination half-life of clozapine 2 weeks after start of fluvoxamine comedication revealed an increase from 17 hours to about 50 hours whereas there was no change under paroxetine coadministration.,Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9472836/),h,17,154901,DB00363,Clozapine
,9472836,elimination half-life,Estimation of the mean elimination half-life of clozapine 2 weeks after start of fluvoxamine comedication revealed an increase from 17 hours to about 50 hours whereas there was no change under paroxetine coadministration.,Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9472836/),h,50,154902,DB00363,Clozapine
,21422906,clearance,The population predicted clearance of clozapine for females was 27.1 L/h (SE 11.1%) and 36.7 L/h (SE 9.7%) for males.,Age and sex impact clozapine plasma concentrations in inpatients and outpatients with schizophrenia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21422906/),[l] / [h],27.1,157703,DB00363,Clozapine
,21422906,clearance,The population predicted clearance of clozapine for females was 27.1 L/h (SE 11.1%) and 36.7 L/h (SE 9.7%) for males.,Age and sex impact clozapine plasma concentrations in inpatients and outpatients with schizophrenia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21422906/),[l] / [h],36.7,157704,DB00363,Clozapine
,21422906,clearance,"For norclozapine, clearance in females was 48.6 L/h (SE 10.8%) and 63.1 L/h (SE 9.3%) in males.",Age and sex impact clozapine plasma concentrations in inpatients and outpatients with schizophrenia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21422906/),[l] / [h],48.6,157705,DB00363,Clozapine
,21422906,clearance,"For norclozapine, clearance in females was 48.6 L/h (SE 10.8%) and 63.1 L/h (SE 9.3%) in males.",Age and sex impact clozapine plasma concentrations in inpatients and outpatients with schizophrenia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21422906/),[l] / [h],63.1,157706,DB00363,Clozapine
,10854834,terminal half-life,We examined the pharmacokinetics and pharmacodynamics of intravenous (1-5 mg/kg) and oral clozapine (2.5-10 mg/kg) in rats (terminal half-life=81.8 min; oral bioavailability=5.32%).,"Intravenous and oral clozapine pharmacokinetics, pharmacodynamics, and concentration-effect relations: acute tolerance. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10854834/),min,81.8,157788,DB00363,Clozapine
,10854834,oral bioavailability,We examined the pharmacokinetics and pharmacodynamics of intravenous (1-5 mg/kg) and oral clozapine (2.5-10 mg/kg) in rats (terminal half-life=81.8 min; oral bioavailability=5.32%).,"Intravenous and oral clozapine pharmacokinetics, pharmacodynamics, and concentration-effect relations: acute tolerance. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10854834/),%,5.32,157789,DB00363,Clozapine
,24934547,terminal half-lives,"Average values of the terminal half-lives of clozapine were calculated to be 10.2, 13.2, 14.2, 18.3 and 29.2 hours with a last data point at 12, 24, 48, 72 and 120 hours, respectively.",Literature values of terminal half-lives of clozapine are dependent on the time of the last data point. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24934547/),h,10.2,163654,DB00363,Clozapine
,24934547,terminal half-lives,"Average values of the terminal half-lives of clozapine were calculated to be 10.2, 13.2, 14.2, 18.3 and 29.2 hours with a last data point at 12, 24, 48, 72 and 120 hours, respectively.",Literature values of terminal half-lives of clozapine are dependent on the time of the last data point. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24934547/),h,13.2,163655,DB00363,Clozapine
,24934547,terminal half-lives,"Average values of the terminal half-lives of clozapine were calculated to be 10.2, 13.2, 14.2, 18.3 and 29.2 hours with a last data point at 12, 24, 48, 72 and 120 hours, respectively.",Literature values of terminal half-lives of clozapine are dependent on the time of the last data point. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24934547/),h,14.2,163656,DB00363,Clozapine
,24934547,terminal half-lives,"Average values of the terminal half-lives of clozapine were calculated to be 10.2, 13.2, 14.2, 18.3 and 29.2 hours with a last data point at 12, 24, 48, 72 and 120 hours, respectively.",Literature values of terminal half-lives of clozapine are dependent on the time of the last data point. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24934547/),h,18.3,163657,DB00363,Clozapine
,24934547,terminal half-lives,"Average values of the terminal half-lives of clozapine were calculated to be 10.2, 13.2, 14.2, 18.3 and 29.2 hours with a last data point at 12, 24, 48, 72 and 120 hours, respectively.",Literature values of terminal half-lives of clozapine are dependent on the time of the last data point. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24934547/),h,29.2,163658,DB00363,Clozapine
,16778724,flow-rate,The chromatographic separation required 6 minutes at a flow-rate of 1.0 mL/min and was carried out on a Water Spherisorb S5 C6 analytical column (250 mm x 4.6 mm ID) with a mobile phase water-acetonitrile 55:45 vol/vol containing 0.009 moL/L eptansulfonic acid sodium salt and 0.06 mol/L potassium phosphate monobasic pH 2.7.,Determination of olanzapine in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778724/),[ml] / [min],1.0,166730,DB00363,Clozapine
,16778724,recoveries,"Mean recoveries for olanzapine and internal standard were 89.4+/-3.3% and 90.4+/-1.0%, respectively.",Determination of olanzapine in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778724/),%,89.4,166731,DB00363,Clozapine
,16778724,recoveries,"Mean recoveries for olanzapine and internal standard were 89.4+/-3.3% and 90.4+/-1.0%, respectively.",Determination of olanzapine in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778724/),%,90.4,166732,DB00363,Clozapine
,16778724,Limit of detection,"Limit of detection and limit of quantification for olanzapine were 2 and 5 ng/mL, respectively.",Determination of olanzapine in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778724/),[ng] / [ml],2,166733,DB00363,Clozapine
,16778724,limit of quantification,"Limit of detection and limit of quantification for olanzapine were 2 and 5 ng/mL, respectively.",Determination of olanzapine in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778724/),[ng] / [ml],5,166734,DB00363,Clozapine
,12544379,CLZ,"CLZ clearance averaged 1.7 L/kg-h. NOR concentrations (410) exceeded CLZ (289) and NOX (63 ng/ml) and AUC(0-8h) of NOR (3,356) > CLZ (2,359) > NOX (559 ng/ml-h) [53, 38, and 9% of total analytes, respectively].",Clozapine pharmacokinetics in children and adolescents with childhood-onset schizophrenia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12544379/),[l] / [kg-h],1.7,173057,DB00363,Clozapine
,12544379,clearance,"CLZ clearance averaged 1.7 L/kg-h. NOR concentrations (410) exceeded CLZ (289) and NOX (63 ng/ml) and AUC(0-8h) of NOR (3,356) > CLZ (2,359) > NOX (559 ng/ml-h) [53, 38, and 9% of total analytes, respectively].",Clozapine pharmacokinetics in children and adolescents with childhood-onset schizophrenia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12544379/),[l] / [kg-h],1.7,173058,DB00363,Clozapine
,12544379,AUC(0-8h),"CLZ clearance averaged 1.7 L/kg-h. NOR concentrations (410) exceeded CLZ (289) and NOX (63 ng/ml) and AUC(0-8h) of NOR (3,356) > CLZ (2,359) > NOX (559 ng/ml-h) [53, 38, and 9% of total analytes, respectively].",Clozapine pharmacokinetics in children and adolescents with childhood-onset schizophrenia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12544379/),[ng] / [ml-h],"3,356",173059,DB00363,Clozapine
,12544379,AUC(0-8h),"CLZ clearance averaged 1.7 L/kg-h. NOR concentrations (410) exceeded CLZ (289) and NOX (63 ng/ml) and AUC(0-8h) of NOR (3,356) > CLZ (2,359) > NOX (559 ng/ml-h) [53, 38, and 9% of total analytes, respectively].",Clozapine pharmacokinetics in children and adolescents with childhood-onset schizophrenia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12544379/),[ng] / [ml-h],"2,359",173060,DB00363,Clozapine
,12544379,AUC(0-8h),"CLZ clearance averaged 1.7 L/kg-h. NOR concentrations (410) exceeded CLZ (289) and NOX (63 ng/ml) and AUC(0-8h) of NOR (3,356) > CLZ (2,359) > NOX (559 ng/ml-h) [53, 38, and 9% of total analytes, respectively].",Clozapine pharmacokinetics in children and adolescents with childhood-onset schizophrenia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12544379/),[ng] / [ml-h],559,173061,DB00363,Clozapine
,12544379,AUC(0-8h),"CLZ clearance averaged 1.7 L/kg-h. NOR concentrations (410) exceeded CLZ (289) and NOX (63 ng/ml) and AUC(0-8h) of NOR (3,356) > CLZ (2,359) > NOX (559 ng/ml-h) [53, 38, and 9% of total analytes, respectively].",Clozapine pharmacokinetics in children and adolescents with childhood-onset schizophrenia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12544379/),%,53,173062,DB00363,Clozapine
,12544379,AUC(0-8h),"CLZ clearance averaged 1.7 L/kg-h. NOR concentrations (410) exceeded CLZ (289) and NOX (63 ng/ml) and AUC(0-8h) of NOR (3,356) > CLZ (2,359) > NOX (559 ng/ml-h) [53, 38, and 9% of total analytes, respectively].",Clozapine pharmacokinetics in children and adolescents with childhood-onset schizophrenia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12544379/),%,38,173063,DB00363,Clozapine
,12544379,AUC(0-8h),"CLZ clearance averaged 1.7 L/kg-h. NOR concentrations (410) exceeded CLZ (289) and NOX (63 ng/ml) and AUC(0-8h) of NOR (3,356) > CLZ (2,359) > NOX (559 ng/ml-h) [53, 38, and 9% of total analytes, respectively].",Clozapine pharmacokinetics in children and adolescents with childhood-onset schizophrenia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12544379/),%,9,173064,DB00363,Clozapine
,30956977,concentration,"Mean ± standard deviation for CZP and NCZP concentration was 421 ± 262 ng/mL and 275 ± 180 ng/mL, respectively.",Population Pharmacokinetics of Clozapine and Norclozapine and Switchability Assessment between Brands in Uruguayan Patients with Schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30956977/),[ng] / [ml],421,176108,DB00363,Clozapine
,30956977,concentration,"Mean ± standard deviation for CZP and NCZP concentration was 421 ± 262 ng/mL and 275 ± 180 ng/mL, respectively.",Population Pharmacokinetics of Clozapine and Norclozapine and Switchability Assessment between Brands in Uruguayan Patients with Schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30956977/),[ng] / [ml],275,176109,DB00363,Clozapine
,9864080,volume of distribution,"The mean volume of distribution and the total plasma clearance, uncorrected for bioavailability, were 6 L/kg and 38 L/hr, respectively.",Multiple-dose pharmacokinetics of clozapine in patients with chronic schizophrenia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9864080/),[l] / [kg],6,176847,DB00363,Clozapine
,9864080,total plasma clearance,"The mean volume of distribution and the total plasma clearance, uncorrected for bioavailability, were 6 L/kg and 38 L/hr, respectively.",Multiple-dose pharmacokinetics of clozapine in patients with chronic schizophrenia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9864080/),[l] / [h],38,176848,DB00363,Clozapine
,9864080,terminal elimination half-lives,"The terminal elimination half-lives averaged 7.6 hours for clozapine, 13 hours for norclozapine, and 7 hours for the N-oxide metabolite.",Multiple-dose pharmacokinetics of clozapine in patients with chronic schizophrenia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9864080/),h,7.6,176849,DB00363,Clozapine
,9864080,terminal elimination half-lives,"The terminal elimination half-lives averaged 7.6 hours for clozapine, 13 hours for norclozapine, and 7 hours for the N-oxide metabolite.",Multiple-dose pharmacokinetics of clozapine in patients with chronic schizophrenia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9864080/),h,13,176850,DB00363,Clozapine
,9864080,terminal elimination half-lives,"The terminal elimination half-lives averaged 7.6 hours for clozapine, 13 hours for norclozapine, and 7 hours for the N-oxide metabolite.",Multiple-dose pharmacokinetics of clozapine in patients with chronic schizophrenia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9864080/),h,7,176851,DB00363,Clozapine
,9864080,RBC/plasma concentration ratios,"The mean RBC/plasma concentration ratios were 23, 61, and 81% for clozapine, N-desmethylclozapine, and clozapine N-oxide, respectively.",Multiple-dose pharmacokinetics of clozapine in patients with chronic schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9864080/),%,23,176852,DB00363,Clozapine
,9864080,RBC/plasma concentration ratios,"The mean RBC/plasma concentration ratios were 23, 61, and 81% for clozapine, N-desmethylclozapine, and clozapine N-oxide, respectively.",Multiple-dose pharmacokinetics of clozapine in patients with chronic schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9864080/),%,61,176853,DB00363,Clozapine
,9864080,RBC/plasma concentration ratios,"The mean RBC/plasma concentration ratios were 23, 61, and 81% for clozapine, N-desmethylclozapine, and clozapine N-oxide, respectively.",Multiple-dose pharmacokinetics of clozapine in patients with chronic schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9864080/),%,81,176854,DB00363,Clozapine
,9864080,elimination half-lives,"From RBC concentration data, the mean elimination half-lives were 7.6 hours for clozapine, 16 hours for N-desmethylclozapine, and 8 hours for the N-oxide metabolite.",Multiple-dose pharmacokinetics of clozapine in patients with chronic schizophrenia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9864080/),h,7.6,176855,DB00363,Clozapine
,9864080,elimination half-lives,"From RBC concentration data, the mean elimination half-lives were 7.6 hours for clozapine, 16 hours for N-desmethylclozapine, and 8 hours for the N-oxide metabolite.",Multiple-dose pharmacokinetics of clozapine in patients with chronic schizophrenia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9864080/),h,16,176856,DB00363,Clozapine
,9864080,elimination half-lives,"From RBC concentration data, the mean elimination half-lives were 7.6 hours for clozapine, 16 hours for N-desmethylclozapine, and 8 hours for the N-oxide metabolite.",Multiple-dose pharmacokinetics of clozapine in patients with chronic schizophrenia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9864080/),h,8,176857,DB00363,Clozapine
,9864080,blood clearance,The average value for blood clearance of clozapine was 54.7 L/hr.,Multiple-dose pharmacokinetics of clozapine in patients with chronic schizophrenia. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9864080/),[l] / [h],54.7,176858,DB00363,Clozapine
,3145517,limit of,The limit of determination was 1.0 ng/ml for clozapine and 5.0 ng/ml norclozapine.,Determination of clozapine and its N-demethylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3145517/),[ng] / [ml],1.0,180023,DB00363,Clozapine
,3145517,limit of,The limit of determination was 1.0 ng/ml for clozapine and 5.0 ng/ml norclozapine.,Determination of clozapine and its N-demethylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3145517/),[ng] / [ml],5.0,180024,DB00363,Clozapine
,33731885,Clz dose-normalized (C0/D ratio),"For CYP1A2*1F, Clz dose-normalized (C0/D ratio) was as high as 1.28 ± 0.37 in CC versus 0.67 ± 0.32 ng mL-1 per mg day-1 in AA group (p < 0.001).",Clinical and genetic influencing factors on clozapine pharmacokinetics in Tunisian schizophrenic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33731885/),[ng] / [d·mg·ml],1.28,182642,DB00363,Clozapine
,33731885,Clz dose-normalized (C0/D ratio),"For CYP1A2*1F, Clz dose-normalized (C0/D ratio) was as high as 1.28 ± 0.37 in CC versus 0.67 ± 0.32 ng mL-1 per mg day-1 in AA group (p < 0.001).",Clinical and genetic influencing factors on clozapine pharmacokinetics in Tunisian schizophrenic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33731885/),[ng] / [d·mg·ml],0.67,182643,DB00363,Clozapine
,19806921,CL/F,"Typical value of CL/F (non-smoking group), V/F and the constant of absorption rate were 28.5 L x h(-1) (5.05%), 1 290 L (16.7%) and 2.26 h(-1) (fixed), inter-patient variability (CV) in CL/F and V/F was) 42.2% and 10.0%, respectively.",[Population pharmacokinetics research of clozapine in Chinese schizophrenic patients]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806921/),[l] / [h],28.5,183076,DB00363,Clozapine
,19806921,V/F,"Typical value of CL/F (non-smoking group), V/F and the constant of absorption rate were 28.5 L x h(-1) (5.05%), 1 290 L (16.7%) and 2.26 h(-1) (fixed), inter-patient variability (CV) in CL/F and V/F was) 42.2% and 10.0%, respectively.",[Population pharmacokinetics research of clozapine in Chinese schizophrenic patients]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806921/),l,1 290,183077,DB00363,Clozapine
,19806921,constant of absorption rate,"Typical value of CL/F (non-smoking group), V/F and the constant of absorption rate were 28.5 L x h(-1) (5.05%), 1 290 L (16.7%) and 2.26 h(-1) (fixed), inter-patient variability (CV) in CL/F and V/F was) 42.2% and 10.0%, respectively.",[Population pharmacokinetics research of clozapine in Chinese schizophrenic patients]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19806921/),1/[h],2.26,183078,DB00363,Clozapine
,28340122,normal,"The patients' CYP2C19 or CYP2D6 genotypes and CYP1A2 expression seemed to have no effect on clozapine serum concentration, whereas CYP3A4 expression significantly influenced the normalized clozapine concentration (185.53±56.53 in low expressers vs 78.05±29.57 or 66.52±0.25 (ng/mL)/(mg/kg) in normal or high expressers, P<.0001), in particular that the patients expressed CYP1A2 at a relatively low level.",Potential Role of Patients' CYP3A-Status in Clozapine Pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28340122/),,78,192965,DB00363,Clozapine
,28340122,normal,"The patients' CYP2C19 or CYP2D6 genotypes and CYP1A2 expression seemed to have no effect on clozapine serum concentration, whereas CYP3A4 expression significantly influenced the normalized clozapine concentration (185.53±56.53 in low expressers vs 78.05±29.57 or 66.52±0.25 (ng/mL)/(mg/kg) in normal or high expressers, P<.0001), in particular that the patients expressed CYP1A2 at a relatively low level.",Potential Role of Patients' CYP3A-Status in Clozapine Pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28340122/),,66,192966,DB00363,Clozapine
,28340122,concentration,"The patients' CYP2C19 or CYP2D6 genotypes and CYP1A2 expression seemed to have no effect on clozapine serum concentration, whereas CYP3A4 expression significantly influenced the normalized clozapine concentration (185.53±56.53 in low expressers vs 78.05±29.57 or 66.52±0.25 (ng/mL)/(mg/kg) in normal or high expressers, P<.0001), in particular that the patients expressed CYP1A2 at a relatively low level.",Potential Role of Patients' CYP3A-Status in Clozapine Pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28340122/),,78,192967,DB00363,Clozapine
,28340122,concentration,"The patients' CYP2C19 or CYP2D6 genotypes and CYP1A2 expression seemed to have no effect on clozapine serum concentration, whereas CYP3A4 expression significantly influenced the normalized clozapine concentration (185.53±56.53 in low expressers vs 78.05±29.57 or 66.52±0.25 (ng/mL)/(mg/kg) in normal or high expressers, P<.0001), in particular that the patients expressed CYP1A2 at a relatively low level.",Potential Role of Patients' CYP3A-Status in Clozapine Pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28340122/),,66,192968,DB00363,Clozapine
,11313155,receptor,Mean D(2) receptor occupancies of 41 and 30% were observed at quetiapine doses of 750 and 450 mg/day.,D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11313155/),%,41,201024,DB00363,Clozapine
,11313155,receptor,Mean D(2) receptor occupancies of 41 and 30% were observed at quetiapine doses of 750 and 450 mg/day.,D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11313155/),%,30,201025,DB00363,Clozapine
,11313155,occupancies,Mean D(2) receptor occupancies of 41 and 30% were observed at quetiapine doses of 750 and 450 mg/day.,D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11313155/),%,41,201026,DB00363,Clozapine
,11313155,occupancies,Mean D(2) receptor occupancies of 41 and 30% were observed at quetiapine doses of 750 and 450 mg/day.,D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11313155/),%,30,201027,DB00363,Clozapine
,11313155,occupancies,"Quetiapine induced a consistently higher degree of 5HT(2A) receptor occupancy, with mean occupancies of 74 and 57% at doses of 750 and 450 mg/day, respectively.",D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11313155/),%,74,201028,DB00363,Clozapine
,11313155,occupancies,"Quetiapine induced a consistently higher degree of 5HT(2A) receptor occupancy, with mean occupancies of 74 and 57% at doses of 750 and 450 mg/day, respectively.",D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11313155/),%,57,201029,DB00363,Clozapine
,18308793,D,"Observed striatal D(2)RO and C(P) ranges were 28-75% and 9.4-60.5 ng/mL for risperidone, 22-84% and 8.6-89.5 ng/mL for olanzapine, 5-53% and 41.6-818.2 ng/mL for clozapine and 0-64% and 37.9-719.6 ng/mL for quetiapine.",Pharmacokinetics and time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18308793/),%,28-75,202598,DB00363,Clozapine
,18308793,RO,"Observed striatal D(2)RO and C(P) ranges were 28-75% and 9.4-60.5 ng/mL for risperidone, 22-84% and 8.6-89.5 ng/mL for olanzapine, 5-53% and 41.6-818.2 ng/mL for clozapine and 0-64% and 37.9-719.6 ng/mL for quetiapine.",Pharmacokinetics and time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18308793/),%,28-75,202599,DB00363,Clozapine
,18308793,C(P),"Observed striatal D(2)RO and C(P) ranges were 28-75% and 9.4-60.5 ng/mL for risperidone, 22-84% and 8.6-89.5 ng/mL for olanzapine, 5-53% and 41.6-818.2 ng/mL for clozapine and 0-64% and 37.9-719.6 ng/mL for quetiapine.",Pharmacokinetics and time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18308793/),[ng] / [ml],9.4-60.5,202600,DB00363,Clozapine
,9766870,flow-rate,"Analytes are eluted at a flow-rate of 1.0 ml/min, separated on a 250 x 4.60 mm I.D. analytical column packed with 5 microm C6 silica particles, and measured by UV absorbance detection at 254 nm.","Determination of clozapine, desmethylclozapine and clozapine N-oxide in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9766870/),[ml] / [min],1.0,213357,DB00363,Clozapine
,9766870,recoveries,"Mean recoveries were 92.7% for clozapine, 82.0% for desmethylclozapine and 70.4% for clozapine N-oxide.","Determination of clozapine, desmethylclozapine and clozapine N-oxide in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9766870/),%,92.7,213358,DB00363,Clozapine
,9766870,recoveries,"Mean recoveries were 92.7% for clozapine, 82.0% for desmethylclozapine and 70.4% for clozapine N-oxide.","Determination of clozapine, desmethylclozapine and clozapine N-oxide in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9766870/),%,82.0,213359,DB00363,Clozapine
,9766870,recoveries,"Mean recoveries were 92.7% for clozapine, 82.0% for desmethylclozapine and 70.4% for clozapine N-oxide.","Determination of clozapine, desmethylclozapine and clozapine N-oxide in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9766870/),%,70.4,213360,DB00363,Clozapine
,34046160,trough concentrations,"A total of 108 patients completed the study (mean ± SD age, 43.0 ± 10.1 years; clozapine dose, 357.5 ± 136.9 mg/day); 33 patients (30.6%) showed estimated trough concentrations of clozapine within the recommended range (350-600 ng/ml) whereas the concentrations were higher and lower than this range among 37 (43.5%) and 28 (25.9%) patients (%), respectively.",Comprehensive assessment of exposure to clozapine in association with side effects among patients with treatment-resistant schizophrenia: a population pharmacokinetic study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34046160/),[ng] / [ml],350-600,214297,DB00363,Clozapine
>,34046160,trough concentrations,No significant differences were found between GASS-C total or individual item scores between the patients with estimated trough concentrations of clozapine of >600 ng/ml and the other subjects.,Comprehensive assessment of exposure to clozapine in association with side effects among patients with treatment-resistant schizophrenia: a population pharmacokinetic study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34046160/),[ng] / [ml],600,214298,DB00363,Clozapine
,24342896,AUC(50) (cAUC(50)),"The maximum decrease in PANSS during clozapine treatment (Emax) was 55.4%, and the cumulated AUC(50) (cAUC(50)) required to attain half of E(max) was 296 mg·L(-1)·h(-1)·d(-1).",Population pharmacokinetic/pharmacodynamic model of clozapine for characterizing the relationship between accumulated exposure and PANSS scores in patients with schizophrenia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24342896/),[mg] / [d·h·l],296,215676,DB00363,Clozapine
,24342896,half of E(max),"The maximum decrease in PANSS during clozapine treatment (Emax) was 55.4%, and the cumulated AUC(50) (cAUC(50)) required to attain half of E(max) was 296 mg·L(-1)·h(-1)·d(-1).",Population pharmacokinetic/pharmacodynamic model of clozapine for characterizing the relationship between accumulated exposure and PANSS scores in patients with schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24342896/),[mg] / [d·h·l],296,215677,DB00363,Clozapine
,11862380,half-life,Occupancy decreased with a half-life of 7.22 h after 5.0 mg/kg clozapine and 5.25 h after 1.0 and 2.0 mg/kg clozapine.,Clozapine can induce high dopamine D(2) receptor occupancy in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862380/),h,7.22,217772,DB00363,Clozapine
,11862380,half-life,Occupancy decreased with a half-life of 7.22 h after 5.0 mg/kg clozapine and 5.25 h after 1.0 and 2.0 mg/kg clozapine.,Clozapine can induce high dopamine D(2) receptor occupancy in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862380/),h,5.25,217773,DB00363,Clozapine
,8453823,time to reach peak plasma concentrations,These studies have revealed a wide interpatient variability in pharmacokinetic parameters that include: time to reach peak plasma concentrations 1.1 to 3.6h; elimination half-life 9.1 to 17.4h; clearance 8.7 to 53.3 L/h; and a volume of distribution of 1.6 to 7.3 L/kg.,Pharmacokinetics and pharmacodynamics of clozapine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453823/),h,1.1 to 3.6,224037,DB00363,Clozapine
,8453823,elimination half-life,These studies have revealed a wide interpatient variability in pharmacokinetic parameters that include: time to reach peak plasma concentrations 1.1 to 3.6h; elimination half-life 9.1 to 17.4h; clearance 8.7 to 53.3 L/h; and a volume of distribution of 1.6 to 7.3 L/kg.,Pharmacokinetics and pharmacodynamics of clozapine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453823/),h,9.1 to 17.4,224038,DB00363,Clozapine
,8453823,clearance,These studies have revealed a wide interpatient variability in pharmacokinetic parameters that include: time to reach peak plasma concentrations 1.1 to 3.6h; elimination half-life 9.1 to 17.4h; clearance 8.7 to 53.3 L/h; and a volume of distribution of 1.6 to 7.3 L/kg.,Pharmacokinetics and pharmacodynamics of clozapine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453823/),[l] / [h],8.7 to 53.3,224039,DB00363,Clozapine
,8453823,volume of distribution,These studies have revealed a wide interpatient variability in pharmacokinetic parameters that include: time to reach peak plasma concentrations 1.1 to 3.6h; elimination half-life 9.1 to 17.4h; clearance 8.7 to 53.3 L/h; and a volume of distribution of 1.6 to 7.3 L/kg.,Pharmacokinetics and pharmacodynamics of clozapine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453823/),[l] / [kg],1.6 to 7.3,224040,DB00363,Clozapine
,8453823,minimum concentration,"In the treatment of patients with refractory schizophrenia, a minimum concentration of 350 micrograms/L was suggested as needed.",Pharmacokinetics and pharmacodynamics of clozapine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453823/),[μg] / [l],350,224041,DB00363,Clozapine
,9698242,detection limit,The detection limit was 2.5 ng/ml for all the compounds using an ultraviolet detector operated at 230 nm.,"Determination of clozapine and its metabolite, N-desmethylclozapine, in serum microsamples by high-performance liquid chromatography and its application to pharmacokinetics in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9698242/),[ng] / [ml],2.5,224675,DB00363,Clozapine
,15121646,occup,"The mean 5-HT(2) receptor occupancy was significantly higher than the mean D(2) receptor occupancy (mean=76%, SD=15%, and mean=56%, SD=18%, respectively).",A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15121646/),%,76,224901,DB00363,Clozapine
,15121646,occup,"The mean 5-HT(2) receptor occupancy was significantly higher than the mean D(2) receptor occupancy (mean=76%, SD=15%, and mean=56%, SD=18%, respectively).",A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15121646/),%,56,224902,DB00363,Clozapine
,24678101,t1/2,"After multiple oral doses (10 mg g12h), the mean (SD) t1/2, Css max, Tmax, MRT, V/F, and CL/F were 62.2 (9.0) hours, 557.3 (135.5) ng/mL, 2.6 (1.1) hours, 84.5 (11.2) hours, 173 (48) L, and 1.9 (0.5) L/h, respectively.","Steady-state pharmacokinetic properties of aripiprazole 10 mg PO g12h in Han Chinese adults with schizophrenia: A prospective, open-label, pilot study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24678101/),h,62.2,228250,DB00363,Clozapine
,24678101,CL/F,"After multiple oral doses (10 mg g12h), the mean (SD) t1/2, Css max, Tmax, MRT, V/F, and CL/F were 62.2 (9.0) hours, 557.3 (135.5) ng/mL, 2.6 (1.1) hours, 84.5 (11.2) hours, 173 (48) L, and 1.9 (0.5) L/h, respectively.","Steady-state pharmacokinetic properties of aripiprazole 10 mg PO g12h in Han Chinese adults with schizophrenia: A prospective, open-label, pilot study. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24678101/),[l] / [h],1.9,228251,DB00363,Clozapine
,24678101,t/12,"In Chinese patients, the t/12 values were numerically similar (62.2 [9.0] vs 68.1 [22.9] hours); Css max values were numerically higher (557.3 [135.5] vs 393 [181 ] ng/mL); and V/F and CL/F values were numerically lower (V/F: 173 [48] vs 196 [66] L; CL/F: 1.9 [0.5] vs 3.4 [1.6] L/h) compared with healthy white male volunteers.","Steady-state pharmacokinetic properties of aripiprazole 10 mg PO g12h in Han Chinese adults with schizophrenia: A prospective, open-label, pilot study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24678101/),h,62.2,228252,DB00363,Clozapine
,24678101,t/12,"In Chinese patients, the t/12 values were numerically similar (62.2 [9.0] vs 68.1 [22.9] hours); Css max values were numerically higher (557.3 [135.5] vs 393 [181 ] ng/mL); and V/F and CL/F values were numerically lower (V/F: 173 [48] vs 196 [66] L; CL/F: 1.9 [0.5] vs 3.4 [1.6] L/h) compared with healthy white male volunteers.","Steady-state pharmacokinetic properties of aripiprazole 10 mg PO g12h in Han Chinese adults with schizophrenia: A prospective, open-label, pilot study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24678101/),h,68.1,228253,DB00363,Clozapine
,24678101,Css max,"In Chinese patients, the t/12 values were numerically similar (62.2 [9.0] vs 68.1 [22.9] hours); Css max values were numerically higher (557.3 [135.5] vs 393 [181 ] ng/mL); and V/F and CL/F values were numerically lower (V/F: 173 [48] vs 196 [66] L; CL/F: 1.9 [0.5] vs 3.4 [1.6] L/h) compared with healthy white male volunteers.","Steady-state pharmacokinetic properties of aripiprazole 10 mg PO g12h in Han Chinese adults with schizophrenia: A prospective, open-label, pilot study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24678101/),[ng] / [ml],557.3,228254,DB00363,Clozapine
,24678101,Css max,"In Chinese patients, the t/12 values were numerically similar (62.2 [9.0] vs 68.1 [22.9] hours); Css max values were numerically higher (557.3 [135.5] vs 393 [181 ] ng/mL); and V/F and CL/F values were numerically lower (V/F: 173 [48] vs 196 [66] L; CL/F: 1.9 [0.5] vs 3.4 [1.6] L/h) compared with healthy white male volunteers.","Steady-state pharmacokinetic properties of aripiprazole 10 mg PO g12h in Han Chinese adults with schizophrenia: A prospective, open-label, pilot study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24678101/),[ng] / [ml],393,228255,DB00363,Clozapine
,24678101,V/F,"In Chinese patients, the t/12 values were numerically similar (62.2 [9.0] vs 68.1 [22.9] hours); Css max values were numerically higher (557.3 [135.5] vs 393 [181 ] ng/mL); and V/F and CL/F values were numerically lower (V/F: 173 [48] vs 196 [66] L; CL/F: 1.9 [0.5] vs 3.4 [1.6] L/h) compared with healthy white male volunteers.","Steady-state pharmacokinetic properties of aripiprazole 10 mg PO g12h in Han Chinese adults with schizophrenia: A prospective, open-label, pilot study. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24678101/),l,173,228256,DB00363,Clozapine
,24678101,V/F,"In Chinese patients, the t/12 values were numerically similar (62.2 [9.0] vs 68.1 [22.9] hours); Css max values were numerically higher (557.3 [135.5] vs 393 [181 ] ng/mL); and V/F and CL/F values were numerically lower (V/F: 173 [48] vs 196 [66] L; CL/F: 1.9 [0.5] vs 3.4 [1.6] L/h) compared with healthy white male volunteers.","Steady-state pharmacokinetic properties of aripiprazole 10 mg PO g12h in Han Chinese adults with schizophrenia: A prospective, open-label, pilot study. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24678101/),l,196,228257,DB00363,Clozapine
,24678101,CL/F,"In Chinese patients, the t/12 values were numerically similar (62.2 [9.0] vs 68.1 [22.9] hours); Css max values were numerically higher (557.3 [135.5] vs 393 [181 ] ng/mL); and V/F and CL/F values were numerically lower (V/F: 173 [48] vs 196 [66] L; CL/F: 1.9 [0.5] vs 3.4 [1.6] L/h) compared with healthy white male volunteers.","Steady-state pharmacokinetic properties of aripiprazole 10 mg PO g12h in Han Chinese adults with schizophrenia: A prospective, open-label, pilot study. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24678101/),[l] / [h],1.9,228258,DB00363,Clozapine
,24678101,CL/F,"In Chinese patients, the t/12 values were numerically similar (62.2 [9.0] vs 68.1 [22.9] hours); Css max values were numerically higher (557.3 [135.5] vs 393 [181 ] ng/mL); and V/F and CL/F values were numerically lower (V/F: 173 [48] vs 196 [66] L; CL/F: 1.9 [0.5] vs 3.4 [1.6] L/h) compared with healthy white male volunteers.","Steady-state pharmacokinetic properties of aripiprazole 10 mg PO g12h in Han Chinese adults with schizophrenia: A prospective, open-label, pilot study. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24678101/),[l] / [h],3.4,228259,DB00363,Clozapine
,12865111,half-life,"However, the duration of symptoms greatly exceeded that predicted by the published 12-h half-life of clozapine and was associated with an unexplained persistence of serum clozapine concentrations.",Delayed recovery associated with persistent serum concentrations after clozapine overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12865111/),h,12,231469,DB00363,Clozapine
,22337805,m/,"The MS-MS ion transitions monitored were m/z 384.1 → 253.1 and 327.0 → 270.0 for quetiapine and clozapine, respectively.",Validated LC-MS-MS method for the determination of quetiapine in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337805/),,384.1,233921,DB00363,Clozapine
,22337805,m/,"The MS-MS ion transitions monitored were m/z 384.1 → 253.1 and 327.0 → 270.0 for quetiapine and clozapine, respectively.",Validated LC-MS-MS method for the determination of quetiapine in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337805/),,253.1,233922,DB00363,Clozapine
,22337805,m/,"The MS-MS ion transitions monitored were m/z 384.1 → 253.1 and 327.0 → 270.0 for quetiapine and clozapine, respectively.",Validated LC-MS-MS method for the determination of quetiapine in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337805/),,327.0,233923,DB00363,Clozapine
over,22337805,extraction recoveries,The extraction recoveries of quetiapine were over 90%.,Validated LC-MS-MS method for the determination of quetiapine in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337805/),%,90,233924,DB00363,Clozapine
,8148222,Cmax,"The mean (s.d.) Cmax was 117 (81) nmol l-1 and the mean AUC(0,24) value was 890 (711) nmol l-1 h.",Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148222/),[nM] / [l],117,234385,DB00363,Clozapine
,8148222,"AUC(0,24)","The mean (s.d.) Cmax was 117 (81) nmol l-1 and the mean AUC(0,24) value was 890 (711) nmol l-1 h.",Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148222/),[h·nM] / [l],890,234386,DB00363,Clozapine
,8148222,"t1/2,z","The value of t1/2,z varied 3-fold with a mean (s.d.) of 13.3 (5.0) h.",Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148222/),h,13.3,234387,DB00363,Clozapine
,21477416,Peak D₂ receptor occupancy,"Peak D₂ receptor occupancy was significantly higher with quetiapine IR than XR in all subjects (50 ± 4% and 32 ± 11%, respectively), consistent with lower peak plasma concentrations for the XR formulation.",Comparison of D₂ dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21477416/),%,50,243487,DB00363,Clozapine
,21477416,Peak D₂ receptor occupancy,"Peak D₂ receptor occupancy was significantly higher with quetiapine IR than XR in all subjects (50 ± 4% and 32 ± 11%, respectively), consistent with lower peak plasma concentrations for the XR formulation.",Comparison of D₂ dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21477416/),%,32,243488,DB00363,Clozapine
,34417726,absolute concentrations,"Patients switching treatment had 23.5% lower absolute concentrations (954 vs. 1245 nmol/L; p < 0.001) and 15.7% lower daily doses (305 vs. 362 mg/day; p < 0.001) of clozapine than did nonswitchers, making the clozapine C/D ratio 9.7% lower in switchers than in nonswitchers after correcting for smoking habits (2.80 vs. 3.10 nmol/L/mg/day; p = 0.032).",Absolute and Dose-Adjusted Serum Concentrations of Clozapine in Patients Switching vs. Maintaining Treatment: An Observational Study of 1979 Patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34417726/),[nM] / [l],954,246115,DB00363,Clozapine
,34417726,absolute concentrations,"Patients switching treatment had 23.5% lower absolute concentrations (954 vs. 1245 nmol/L; p < 0.001) and 15.7% lower daily doses (305 vs. 362 mg/day; p < 0.001) of clozapine than did nonswitchers, making the clozapine C/D ratio 9.7% lower in switchers than in nonswitchers after correcting for smoking habits (2.80 vs. 3.10 nmol/L/mg/day; p = 0.032).",Absolute and Dose-Adjusted Serum Concentrations of Clozapine in Patients Switching vs. Maintaining Treatment: An Observational Study of 1979 Patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34417726/),[nM] / [l],1245,246116,DB00363,Clozapine
,34417726,C/D ratio,"Patients switching treatment had 23.5% lower absolute concentrations (954 vs. 1245 nmol/L; p < 0.001) and 15.7% lower daily doses (305 vs. 362 mg/day; p < 0.001) of clozapine than did nonswitchers, making the clozapine C/D ratio 9.7% lower in switchers than in nonswitchers after correcting for smoking habits (2.80 vs. 3.10 nmol/L/mg/day; p = 0.032).",Absolute and Dose-Adjusted Serum Concentrations of Clozapine in Patients Switching vs. Maintaining Treatment: An Observational Study of 1979 Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34417726/),[nM] / [d·l·mg],2.80,246117,DB00363,Clozapine
,34417726,C/D ratio,"Patients switching treatment had 23.5% lower absolute concentrations (954 vs. 1245 nmol/L; p < 0.001) and 15.7% lower daily doses (305 vs. 362 mg/day; p < 0.001) of clozapine than did nonswitchers, making the clozapine C/D ratio 9.7% lower in switchers than in nonswitchers after correcting for smoking habits (2.80 vs. 3.10 nmol/L/mg/day; p = 0.032).",Absolute and Dose-Adjusted Serum Concentrations of Clozapine in Patients Switching vs. Maintaining Treatment: An Observational Study of 1979 Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34417726/),[nM] / [d·l·mg],3.10,246118,DB00363,Clozapine
,7619892,Tmax,"The drug was rapidly absorbed (Tmax ranged from 1.1 to 3.7 h) and showed a mean terminal elimination half-life of 8.1 h, which was independent of dose.",Quantitative determination and pharmacokinetics of a new antipsychotic (CGS 13429A) in human plasma using capillary gas chromatography/mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7619892/),h,1.1 to 3.7,249088,DB00363,Clozapine
,7619892,terminal elimination half-life,"The drug was rapidly absorbed (Tmax ranged from 1.1 to 3.7 h) and showed a mean terminal elimination half-life of 8.1 h, which was independent of dose.",Quantitative determination and pharmacokinetics of a new antipsychotic (CGS 13429A) in human plasma using capillary gas chromatography/mass spectrometry. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7619892/),h,8.1,249089,DB00363,Clozapine
,10866334,peak clozapine,"Measured peak clozapine and norclozapine concentrations were 3.53 mg/L and 0.70 mg/L, respectively.",Monitoring of clozapine and norclozapine plasma concentration-time curves in acute overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10866334/),[mg] / [l],3.53,249565,DB00363,Clozapine
,10866334,norclozapine concentrations,"Measured peak clozapine and norclozapine concentrations were 3.53 mg/L and 0.70 mg/L, respectively.",Monitoring of clozapine and norclozapine plasma concentration-time curves in acute overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10866334/),[mg] / [l],0.70,249566,DB00363,Clozapine
,10866334,Terminal elimination half-lives,"Terminal elimination half-lives were 16.9 hours and 22.5 hours for clozapine and norclozapine, respectively.",Monitoring of clozapine and norclozapine plasma concentration-time curves in acute overdose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10866334/),h,16.9,249567,DB00363,Clozapine
,10866334,Terminal elimination half-lives,"Terminal elimination half-lives were 16.9 hours and 22.5 hours for clozapine and norclozapine, respectively.",Monitoring of clozapine and norclozapine plasma concentration-time curves in acute overdose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10866334/),h,22.5,249568,DB00363,Clozapine
,10392327,volume of distribution,"The mean volume of distribution and the total plasma clearance of clozapine, uncorrected for bioavailability, were 7 L/kg and 40.5 L/h, respectively.",Clozapine and metabolite concentrations during treatment of patients with chronic schizophrenia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392327/),[l] / [kg],7,257583,DB00363,Clozapine
,10392327,total plasma clearance,"The mean volume of distribution and the total plasma clearance of clozapine, uncorrected for bioavailability, were 7 L/kg and 40.5 L/h, respectively.",Clozapine and metabolite concentrations during treatment of patients with chronic schizophrenia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392327/),[l] / [h],40.5,257584,DB00363,Clozapine
,10392327,terminal elimination half-lives,"The terminal elimination half-lives averaged 10.5 hours for clozapine, 19.2 hours for norclozapine, and 8.6 hours for the N-oxide metabolite.",Clozapine and metabolite concentrations during treatment of patients with chronic schizophrenia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392327/),h,10.5,257585,DB00363,Clozapine
,10392327,terminal elimination half-lives,"The terminal elimination half-lives averaged 10.5 hours for clozapine, 19.2 hours for norclozapine, and 8.6 hours for the N-oxide metabolite.",Clozapine and metabolite concentrations during treatment of patients with chronic schizophrenia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392327/),h,19.2,257586,DB00363,Clozapine
,10392327,terminal elimination half-lives,"The terminal elimination half-lives averaged 10.5 hours for clozapine, 19.2 hours for norclozapine, and 8.6 hours for the N-oxide metabolite.",Clozapine and metabolite concentrations during treatment of patients with chronic schizophrenia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392327/),h,8.6,257587,DB00363,Clozapine
,22794154,Tmax,"The Tmax and T1/2 for the test formulation were 2.26 and 10.92 h, respectively.",Comparative bioavailability of two oral formulations of clozapine in steady state administered in schizophrenic volunteers under individualized dose regime. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22794154/),h,2.26,258181,DB00363,Clozapine
,22794154,T1/2,"The Tmax and T1/2 for the test formulation were 2.26 and 10.92 h, respectively.",Comparative bioavailability of two oral formulations of clozapine in steady state administered in schizophrenic volunteers under individualized dose regime. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22794154/),h,10.92,258182,DB00363,Clozapine
,22794154,Tmax,"In addition, the Tmax and T1/2 for the reference formulation were 2.44 and 11.08 h, respectively.",Comparative bioavailability of two oral formulations of clozapine in steady state administered in schizophrenic volunteers under individualized dose regime. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22794154/),h,2.44,258183,DB00363,Clozapine
,22794154,T1/2,"In addition, the Tmax and T1/2 for the reference formulation were 2.44 and 11.08 h, respectively.",Comparative bioavailability of two oral formulations of clozapine in steady state administered in schizophrenic volunteers under individualized dose regime. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22794154/),h,11.08,258184,DB00363,Clozapine
,8006199,oral clearance,"The mean (SD) oral clearance and half-life of clozapine were 55.4 (29.7) L/hr and 13.7 (9.9) hours, respectively.",Disposition of clozapine and desmethylclozapine in schizophrenic patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8006199/),[l] / [h],55.4,261122,DB00363,Clozapine
,8006199,half-life,"The mean (SD) oral clearance and half-life of clozapine were 55.4 (29.7) L/hr and 13.7 (9.9) hours, respectively.",Disposition of clozapine and desmethylclozapine in schizophrenic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8006199/),h,13.7,261123,DB00363,Clozapine
,8006199,AUC,"The mean (SD) AUC for clozapine and desmethylclozapine was 2389.9 (1406) and 751.1 (622.9) ng.hr/mL, respectively.",Disposition of clozapine and desmethylclozapine in schizophrenic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8006199/),[h·ng] / [ml],2389.9,261124,DB00363,Clozapine
,8006199,AUC,"The mean (SD) AUC for clozapine and desmethylclozapine was 2389.9 (1406) and 751.1 (622.9) ng.hr/mL, respectively.",Disposition of clozapine and desmethylclozapine in schizophrenic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8006199/),[h·ng] / [ml],751.1,261125,DB00363,Clozapine
,17431927,weight-corrected dose,"The mean clozapine dose was significantly higher in the Caucasian subjects (432.5+/-194.7 mg) as compared to the Asian subjects (175.6+/-106.9 mg) (p<0.001) while the mean weight-corrected dose for Asian patients was lower (3.0+/-1.9 and 5.0+/-2.1 mg/kg, respectively, p=0.005).",Metabolic differences between Asian and Caucasian patients on clozapine treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17431927/),,3.0,266026,DB00363,Clozapine
,17431927,weight-corrected dose,"The mean clozapine dose was significantly higher in the Caucasian subjects (432.5+/-194.7 mg) as compared to the Asian subjects (175.6+/-106.9 mg) (p<0.001) while the mean weight-corrected dose for Asian patients was lower (3.0+/-1.9 and 5.0+/-2.1 mg/kg, respectively, p=0.005).",Metabolic differences between Asian and Caucasian patients on clozapine treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17431927/),,5.0,266027,DB00363,Clozapine
,17431927,plasma clo,"There were, however, no ethnic differences in the mean plasma clozapine concentration (415.3+/-185.8 ng/ml in Caucasians and 417.1+/-290.8 ng/ml in Asians).",Metabolic differences between Asian and Caucasian patients on clozapine treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17431927/),[ng] / [ml],415.3,266028,DB00363,Clozapine
,17431927,concentration,"There were, however, no ethnic differences in the mean plasma clozapine concentration (415.3+/-185.8 ng/ml in Caucasians and 417.1+/-290.8 ng/ml in Asians).",Metabolic differences between Asian and Caucasian patients on clozapine treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17431927/),[ng] / [ml],415.3,266029,DB00363,Clozapine
,17431927,concentration,"There were, however, no ethnic differences in the mean plasma clozapine concentration (415.3+/-185.8 ng/ml in Caucasians and 417.1+/-290.8 ng/ml in Asians).",Metabolic differences between Asian and Caucasian patients on clozapine treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17431927/),[ng] / [ml],417.1,266030,DB00363,Clozapine
,12482480,recovery rates,"The recovery rates for clozapine, N-desmethylclozapine, and the internal standard (I.S.) were close to 100% using this method.","Determination of clozapine, and its metabolites, N-desmethylclozapine and clozapine N-oxide in dog plasma using high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12482480/),%,100,268398,DB00363,Clozapine
,12482480,recovery rate,The recovery rate for clozapine N-oxide (62-66%) was lower as expected because it is more polar.,"Determination of clozapine, and its metabolites, N-desmethylclozapine and clozapine N-oxide in dog plasma using high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12482480/),%,62-66,268399,DB00363,Clozapine
,3203703,equilibrium-state concentration ratio,The mean equilibrium-state concentration ratio between blood and plasma was experimentally determined to be 0.87.,Clinical pharmacokinetics of clozapine in chronic schizophrenic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203703/),,0.87,270230,DB00363,Clozapine
,3203703,blood clearance,"The average values for blood clearance, hepatic extraction ratio and oral bioavailability were 250 ml/min, 0.2 and 0.27, respectively.",Clinical pharmacokinetics of clozapine in chronic schizophrenic patients. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203703/),[ml] / [min],250,270231,DB00363,Clozapine
,3203703,hepatic extraction ratio,"The average values for blood clearance, hepatic extraction ratio and oral bioavailability were 250 ml/min, 0.2 and 0.27, respectively.",Clinical pharmacokinetics of clozapine in chronic schizophrenic patients. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203703/),,0.2,270232,DB00363,Clozapine
,3203703,oral bioavailability,"The average values for blood clearance, hepatic extraction ratio and oral bioavailability were 250 ml/min, 0.2 and 0.27, respectively.",Clinical pharmacokinetics of clozapine in chronic schizophrenic patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203703/),,0.27,270233,DB00363,Clozapine
,3203703,volume of distribution at steady-state,"The mean volume of distribution at steady-state and the terminal half-life was 1.6 l/kg and 10.3 h, respectively.",Clinical pharmacokinetics of clozapine in chronic schizophrenic patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203703/),[l] / [kg],1.6,270234,DB00363,Clozapine
,3203703,terminal half-life,"The mean volume of distribution at steady-state and the terminal half-life was 1.6 l/kg and 10.3 h, respectively.",Clinical pharmacokinetics of clozapine in chronic schizophrenic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203703/),h,10.3,270235,DB00363,Clozapine
,17038872,plasma concentrations,"The mean plasma concentrations of olanzapine were 31 +/- 7 ng/mL at baseline, 32 +/- 7 ng/mL at week 6, and 36 +/- 9 ng/mL at week 10, the difference between week 10 and baseline being statistically significant (P < 0.05).","Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038872/),[ng] / [ml],31,272547,DB00363,Clozapine
,17038872,plasma concentrations,"The mean plasma concentrations of olanzapine were 31 +/- 7 ng/mL at baseline, 32 +/- 7 ng/mL at week 6, and 36 +/- 9 ng/mL at week 10, the difference between week 10 and baseline being statistically significant (P < 0.05).","Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038872/),[ng] / [ml],32,272548,DB00363,Clozapine
,17038872,plasma concentrations,"The mean plasma concentrations of olanzapine were 31 +/- 7 ng/mL at baseline, 32 +/- 7 ng/mL at week 6, and 36 +/- 9 ng/mL at week 10, the difference between week 10 and baseline being statistically significant (P < 0.05).","Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038872/),[ng] / [ml],36,272549,DB00363,Clozapine
,22258279,abundance,"Estimated hepatic CYP1A2 abundance values were 52, 64, 79, 90, and 94 pmol/mg microsomal protein for subjects smoking 0, 1-5, 6-10, 11-20, and >20 cigarettes/day respectively.",Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22258279/),[pM] / [mg],52,273907,DB00363,Clozapine
,22258279,abundance,"Estimated hepatic CYP1A2 abundance values were 52, 64, 79, 90, and 94 pmol/mg microsomal protein for subjects smoking 0, 1-5, 6-10, 11-20, and >20 cigarettes/day respectively.",Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22258279/),[pM] / [mg],64,273908,DB00363,Clozapine
,22258279,abundance,"Estimated hepatic CYP1A2 abundance values were 52, 64, 79, 90, and 94 pmol/mg microsomal protein for subjects smoking 0, 1-5, 6-10, 11-20, and >20 cigarettes/day respectively.",Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22258279/),[pM] / [mg],79,273909,DB00363,Clozapine
,22258279,abundance,"Estimated hepatic CYP1A2 abundance values were 52, 64, 79, 90, and 94 pmol/mg microsomal protein for subjects smoking 0, 1-5, 6-10, 11-20, and >20 cigarettes/day respectively.",Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22258279/),[pM] / [mg],90,273910,DB00363,Clozapine
,22258279,abundance,"Estimated hepatic CYP1A2 abundance values were 52, 64, 79, 90, and 94 pmol/mg microsomal protein for subjects smoking 0, 1-5, 6-10, 11-20, and >20 cigarettes/day respectively.",Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22258279/),[pM] / [mg],94,273911,DB00363,Clozapine
,22258279,oral clearance,"The validated model was able to recover the smoking-induced increase in oral clearance of PF-2400013; predicted and observed mean (CV%) values in male nonsmokers and smokers were 90 L/h (40%) and 141 L/h (34%) respectively, and 100 L/h (58%) and 131 L/h (33%) respectively.",Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22258279/),[l] / [h],141,273912,DB00363,Clozapine
,22258279,oral clearance,"The validated model was able to recover the smoking-induced increase in oral clearance of PF-2400013; predicted and observed mean (CV%) values in male nonsmokers and smokers were 90 L/h (40%) and 141 L/h (34%) respectively, and 100 L/h (58%) and 131 L/h (33%) respectively.",Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22258279/),[l] / [h],100,273913,DB00363,Clozapine
,22258279,oral clearance,"The validated model was able to recover the smoking-induced increase in oral clearance of PF-2400013; predicted and observed mean (CV%) values in male nonsmokers and smokers were 90 L/h (40%) and 141 L/h (34%) respectively, and 100 L/h (58%) and 131 L/h (33%) respectively.",Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22258279/),[l] / [h],131,273914,DB00363,Clozapine
